[10-Q] NovaBay Pharmaceuticals, Inc. Quarterly Earnings Report
NovaBay Pharmaceuticals (NBY) filed its Q3 2025 10‑Q, showing a much smaller continuing operation after selling key brands and assets. For the quarter, product revenue was $521 thousand with gross profit of $42 thousand. Operating expenses were $1.30 million, resulting in an operating loss of $1.26 million and a net loss from continuing operations of $1.33 million. Including discontinued operations, the quarter’s net loss was $1.29 million.
Year‑to‑date, discontinued operations contributed $11.08 million of income, driving consolidated net income of $4.46 million despite a $6.63 million loss from continuing operations. Cash and cash equivalents were $2.31 million at September 30, 2025, total assets were $3.49 million, and total liabilities were $1.85 million, with stockholders’ equity at $1.11 million. The company effected a 1‑for‑35 reverse split in 2024 and reported 126,010,749 common shares outstanding as of November 4, 2025.
Management states existing cash, plus proceeds from subsequent Series E Preferred and October 2025 pre‑funded warrants, are expected to fund planned expenses at least through November 7, 2026. The board abandoned a previously approved plan of dissolution and is evaluating opportunities in emerging financial infrastructure and network‑based markets, which may include select blockchain‑based assets.
- None.
- None.
Insights
Lean core remains after divestitures; liquidity runway disclosed.
NovaBay now reports a streamlined continuing business with modest Q3 sales (
Balance sheet metrics show
The board reversed course on dissolution and is assessing “emerging financial infrastructure and network‑based” opportunities, potentially including blockchain assets. Actual impact will depend on future capital deployment and execution details to be disclosed in subsequent filings.
Table of Contents
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
(Mark One)
|
|
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the quarterly period ended
OR
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
For the transition period from to
Commission file number
(Exact name of registrant as specified in its charter)
|
|
|
|
(State or other jurisdiction of incorporation or organization) |
(I.R.S. Employer Identification No.) |
(Address of principal executive offices) (Zip Code)
Registrant’s Telephone Number, Including Area Code: (
Securities Registered Pursuant to Section 12(b) of the Act:
|
Title of Each Class |
Trading Symbol(s) |
Name of Each Exchange On Which Registered |
|
|
|
|
Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.
Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
Large accelerated filer |
☐ |
Accelerated filer |
☐ |
Emerging growth company |
|
|
|
☒ |
Smaller reporting company |
|
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes
As of November 4, 2025, there were
NOVABAY PHARMACEUTICALS, INC.
TABLE OF CONTENTS
PART I
FINANCIAL INFORMATION
|
Item 1. |
Financial Statements |
3 |
|
Condensed Consolidated Balance Sheets: September 30, 2025 (unaudited) and December 31, 2024 |
3 |
|
|
Condensed Consolidated Statements of Operations: Three and nine months ended September 30, 2025 and 2024 (unaudited) |
4 |
|
|
Condensed Consolidated Statements of Stockholders’ Equity (Deficit): Three and nine months ended September 30, 2025 and 2024 (unaudited) |
5 |
|
|
Condensed Consolidated Statements of Cash Flows: Nine months ended September 30, 2025 and 2024 (unaudited) |
6 |
|
|
Notes to Condensed Consolidated Financial Statements (unaudited) |
7 |
|
|
Item 2. |
Management’s Discussion and Analysis of Financial Condition and Results of Operations |
33 |
|
Item 3. |
Quantitative and Qualitative Disclosures About Market Risk |
39 |
|
Item 4. |
Controls and Procedures |
39 |
PART II
OTHER INFORMATION
|
Item 1. |
Legal Proceedings |
40 |
|
Item 1A. |
Risk Factors |
40 |
|
Item 2. |
Unregistered Sales of Equity Securities and Use of Proceeds |
41 |
|
Item 3. |
Defaults Upon Senior Securities |
42 |
|
Item 4. |
Mine Safety Disclosures |
42 |
|
Item 5. |
Other Information |
42 |
|
Item 6. |
Exhibits |
43 |
|
SIGNATURES |
45 |
|
Unless the context requires otherwise, all references in this report to “we,” “our,” “us,” the “Company” and “NovaBay” refer to NovaBay Pharmaceuticals, Inc., a Delaware corporation, and, where applicable, also its former wholly-owned subsidiary, DERMAdoctor, LLC, a Missouri limited liability company (“DERMAdoctor”).
The Company previously owned live trademark registrations in the U.S., as well as trademark registrations and pending applications in many other countries internationally. We sold our primary trademark, “Avenova®”, to PRN Physician Recommended Nutriceuticals, LLC, a Delaware limited liability company, effective on January 17, 2025. We sold our “PhaseOne®” and “NeutroPhase®” U.S. trademarks to PhaseOne Health LLC, a Tennessee limited liability company effective on January 8, 2025. The “DERMAdoctor®”, trademark is held directly by our former wholly-owned subsidiary DERMAdoctor.
On May 30, 2024, we effected a 1-for-35 reverse stock split of our common stock (the “Reverse Stock Split”). Except as otherwise specifically noted, all share numbers, share prices, exercise/conversion prices and per share amounts in this report have been adjusted, on a retroactive basis, to reflect the Reverse Stock Split.
PART I
FINANCIAL INFORMATION
|
ITEM 1. |
FINANCIAL STATEMENTS |
NOVABAY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(in thousands, except par value amounts)
|
September 30, 2025 |
December 31, 2024 |
|||||||
|
(Unaudited) |
||||||||
|
ASSETS |
||||||||
|
Current assets: |
||||||||
|
Cash and cash equivalents |
$ | $ | ||||||
|
Accounts receivable, net |
||||||||
|
Prepaid expenses and other current assets |
||||||||
|
Current assets, discontinued operations |
||||||||
|
Total current assets |
||||||||
|
Operating lease right-of-use assets |
||||||||
|
Property and equipment, net |
||||||||
|
Other assets |
||||||||
|
Other assets, discontinued operations |
||||||||
|
TOTAL ASSETS |
$ | $ | ||||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) |
||||||||
|
Liabilities: |
||||||||
|
Current liabilities: |
||||||||
|
Accounts payable |
$ | $ | ||||||
|
Accrued liabilities |
||||||||
|
Bridge Loan |
||||||||
|
Unsecured Convertible Notes, net of discounts |
||||||||
|
Operating lease liabilities |
||||||||
|
Current liabilities, discontinued operations |
||||||||
|
Total current liabilities |
||||||||
|
Operating lease liabilities-non-current |
||||||||
|
Total liabilities |
||||||||
|
Commitments and contingencies (Note 7) |
|
|
||||||
|
Mezzanine (temporary) equity: |
||||||||
|
Series F Preferred Stock; |
||||||||
|
Stockholders’ equity (deficit): |
||||||||
|
Preferred stock, $ |
||||||||
|
Series B Preferred Stock; |
||||||||
|
Series D Preferred Stock; |
||||||||
|
Common stock, $ |
||||||||
|
Additional paid-in capital |
||||||||
|
Accumulated deficit |
( |
) | ( |
) | ||||
|
Total stockholders’ equity (deficit) |
( |
) | ||||||
|
TOTAL LIABILITIES, MEZZANINE EQUITY AND STOCKHOLDERS’ EQUITY (DEFICIT) |
$ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
NOVABAY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(Unaudited)
(in thousands, except per share data)
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Sales: |
||||||||||||||||
|
Product revenue, net |
$ | $ | $ | $ | ||||||||||||
|
Cost of goods sold |
||||||||||||||||
|
Gross profit |
||||||||||||||||
|
Operating expenses: |
||||||||||||||||
|
General and administrative |
||||||||||||||||
|
Impairment of long-lived assets |
||||||||||||||||
|
Total operating expenses |
||||||||||||||||
|
Operating loss |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Non-cash gain on changes in fair value of warrant liabilities |
||||||||||||||||
|
Non-cash loss on change in fair value of embedded derivative liability |
( |
) | ||||||||||||||
|
Accretion of interest and amortization of discounts on convertible notes |
( |
) | ( |
) | ||||||||||||
|
Extinguishment of Secured Convertible Notes |
( |
) | ( |
) | ||||||||||||
|
Other expense, net |
( |
) | ( |
) | ( |
) | ||||||||||
|
Net loss from continuing operations |
( |
) | ( |
) | ( |
) | ( |
) | ||||||||
|
Net income from discontinued operations, net of taxes (Notes 14, 15 and 16) |
||||||||||||||||
|
Net (loss) income |
( |
) | ( |
) | ( |
) | ||||||||||
|
Less: Increase to accumulated deficit due to adjustment to common stock warrant exercise price |
( |
) | ( |
) | ||||||||||||
|
Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price |
( |
) | ||||||||||||||
|
Net (loss) income attributable to common stockholders |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
|
Weighted average shares outstanding: |
||||||||||||||||
|
Basic (and diluted for net loss) |
||||||||||||||||
|
Diluted earnings (loss) per share attributable to common stockholders |
||||||||||||||||
|
Basic and diluted net income (loss) per share attributable to common stockholders: |
||||||||||||||||
|
Basic loss per share from continuing operations |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Basic earnings per share from discontinued operations |
||||||||||||||||
|
Basic (loss) earnings per share attributable to common stockholders |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
|
Diluted loss per share from continuing operations |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Diluted earnings per share from discontinued operations |
||||||||||||||||
|
Diluted (loss) earnings per share attributable to common stockholders |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
NOVABAY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS’ EQUITY (DEFICIT)
(Unaudited)
(in thousands)
|
Redeemable Preferred Stock |
Preferred Stock |
Common Stock |
Additional Paid- in |
Accumulated |
Total Stockholders’ (Deficit) |
|||||||||||||||||||||||||||||||
| Shares | Amount |
Shares |
Amount |
Shares |
Amount |
Capital |
Deficit |
Equity |
||||||||||||||||||||||||||||
|
Balance at December 31, 2024 |
- | $ | - | $ | $ | $ | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||||
|
Net income |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Exercise of Series F-2 Warrants |
- | - | ||||||||||||||||||||||||||||||||||
|
Exercise of Series F-3 Warrants |
- | - | ||||||||||||||||||||||||||||||||||
|
Repurchase of Series F-1 and F-3 Warrants |
- | - | - | - | - | ( |
) | ( |
) | |||||||||||||||||||||||||||
|
Stock-based compensation expense related to employee and director stock awards |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Balance at March 31, 2025 |
- | $ | - | $ | $ | $ | $ | ( |
) | $ | ||||||||||||||||||||||||||
|
Net loss |
- | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Repurchase of Series F-1 and F-3 Warrants |
- | - | - | - | - | ( |
) | ( |
) | |||||||||||||||||||||||||||
|
Stock-based compensation expense related to employee and director stock awards |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Vesting of director restricted stock awards |
- | - | ||||||||||||||||||||||||||||||||||
|
Balance at June 30, 2025 |
- | $ | - | $ | $ | $ | $ | ( |
) | $ | ||||||||||||||||||||||||||
|
Net loss |
- | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Issuance of Series D Preferred Stock, net of offering costs |
- | - | ||||||||||||||||||||||||||||||||||
|
Issuance of Series F Preferred Stock and Cancellation of Warrants in conjunction with Series F Agreements |
- | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
Deemed Capital Contribution pursuant to Series F Agreements |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
|
Exercise of June 2024 Warrants |
- | - | ||||||||||||||||||||||||||||||||||
|
Exercise of Series F-1 Warrants |
- | - | ||||||||||||||||||||||||||||||||||
|
Exercise of Series F-3 Warrants |
- | - | ||||||||||||||||||||||||||||||||||
|
Dividend Paid |
- | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Balance at September 30, 2025 |
$ | $ | $ | $ | $ | ( |
) | $ | ||||||||||||||||||||||||||||
|
Redeemable Preferred Stock |
Preferred Stock |
Common Stock |
Additional Paid- in |
Accumulated |
Total Stockholders’ (Deficit) |
|||||||||||||||||||||||||||||||
| Shares | Amount |
Shares |
Amount |
Shares |
Amount |
Capital |
Deficit |
Equity |
||||||||||||||||||||||||||||
|
Balance at December 31, 2023 |
- | $ | - | $ | $ | $ | $ | ( |
) | $ | ||||||||||||||||||||||||||
|
Net loss |
- | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Conversion of Series B Preferred Stock to common stock |
- | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
Conversion of Series C Preferred Stock to common stock |
- | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
Adjustment of Series C Preferred Stock conversion price |
- | - | - | - | ( |
) | ||||||||||||||||||||||||||||||
|
Stock-based compensation expense related to employee and director stock awards |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Balance at March 31, 2024 |
- | $ | - | $ | $ | $ | $ | ( |
) | $ | ||||||||||||||||||||||||||
|
Net loss |
- | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Conversion of Series B Preferred Stock to common stock |
- | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
Conversion of Series C Preferred Stock to common stock |
- | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||||
|
Modification of common stock warrants in connection with 2024 Warrant Reprice Transaction |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Issuance of common stock in connection with 2024 Warrant Reprice Transaction, net of offering costs |
- | - | ||||||||||||||||||||||||||||||||||
|
Reclassification of December 2023 Warrants from liability |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Reclassification of March 2024 Warrants from liability |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Reclassification of embedded derivative liability |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Shares issued for |
- | - | ( |
) | ||||||||||||||||||||||||||||||||
|
Stock-based compensation expense related to employee and director stock awards |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Vesting of director restricted stock awards |
- | - | - | 0 | ||||||||||||||||||||||||||||||||
|
Balance at June 30, 2024 |
- | $ | - | $ | $ | $ | $ | ( |
) | $ | ( |
) | ||||||||||||||||||||||||
|
Net loss |
- | - | - | - | ( |
) | ( |
) | ||||||||||||||||||||||||||||
|
Issuance of common stock and prefunded warrants in an underwritten registered direct offering, net of issuance cost |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Exercise of pre-funded warrants |
- | - | - | - | ||||||||||||||||||||||||||||||||
|
Adjustment to common stock warrant exercise price |
- | - | - | - | - | - | ( |
) | ||||||||||||||||||||||||||||
|
Stock-based compensation expense related to employee and director stock awards |
- | - | - | - | - | - | - | |||||||||||||||||||||||||||||
|
Balance at September 30, 2024 |
- | $ | - | $ | $ | $ | $ | ( |
) | $ | ||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
NOVABAY PHARMACEUTICALS, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(Unaudited)
(In thousands)
|
Nine Months Ended September 30, |
||||||||
|
2025 |
2024 |
|||||||
|
Operating activities: |
||||||||
|
Net income (loss) |
$ | $ | ( |
) | ||||
|
Net income from discontinued operations, net of taxes |
( |
) | ( |
) | ||||
|
Adjustments to reconcile net income (loss) to net cash used in operating activities: |
||||||||
|
Depreciation of property and equipment |
||||||||
|
Stock-based compensation expense related to employee and director stock awards |
||||||||
|
Non-cash expense incurred to obtain consent of Secured Convertible Note holders |
||||||||
|
Non-cash gain on changes in fair value of warrant liability |
( |
) | ||||||
|
Non-cash loss on changes in fair value of embedded derivative liability |
||||||||
|
Non-cash loss on modification of warrants |
||||||||
|
Non-cash right-of-use asset amortization |
||||||||
|
Non-cash impairment of long-lived assets |
||||||||
|
Accretion of interest and amortization of debt discounts on convertible notes |
||||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
( |
) | ||||||
|
Prepaid expenses and other current assets |
( |
) | ||||||
|
Other assets |
( |
) | ||||||
|
Accounts payable and accrued liabilities |
( |
) | ||||||
|
Operating lease liabilities |
( |
) | ( |
) | ||||
|
Net cash used in operating activities, continuing operations |
( |
) | ( |
) | ||||
|
Investing activities: |
||||||||
|
Purchases of property and equipment |
( |
) | ||||||
|
Net cash used in investing activities, continuing operations |
( |
) | ||||||
|
Financing activities: |
||||||||
|
Net proceeds from issuance of Series D Preferred Stock |
||||||||
|
Cash payment pursuant to Series F Agreements |
( |
) | ||||||
|
Proceeds from warrant exercises |
||||||||
|
Proceeds from issuance of common stock and pre-funded warrants in an underwritten registered direct offering, net of issuance costs |
||||||||
|
Payments on Secured Convertible Notes |
( |
) | ||||||
|
Repurchase of Series F-1 and F-3 Warrants |
( |
) | ||||||
|
Payment on Bridge Note |
( |
) | ||||||
|
Dividend paid |
( |
) | ||||||
|
Cash debt issuance cost |
( |
) | ||||||
|
Net cash (used in) provided by financing activities, continuing operations |
( |
) | ||||||
|
Net decrease in cash, cash equivalents, and restricted cash, continuing operations |
( |
) | ( |
) | ||||
|
Net increase in cash and cash equivalents, discontinued operations |
||||||||
|
Net increase (decrease) in cash, cash equivalents, and restricted cash, consolidated |
( |
) | ||||||
|
Cash, cash equivalents and restricted cash, beginning of period |
||||||||
|
Cash, cash equivalents and restricted cash of continuing operations, end of period |
$ | $ | ||||||
|
Nine Months Ended September 30, |
||||||||
|
2025 |
2024 |
|||||||
|
Supplemental disclosure of cash flow information: |
||||||||
|
Interest paid |
$ | $ | ||||||
|
Supplemental disclosure of non-cash information: |
||||||||
|
Cancellation of Common Stock Warrants pursuant to Series F Agreements |
$ | $ | ||||||
|
Deemed Capital Contribution |
||||||||
|
Conversions of preferred stock to common stock |
||||||||
|
Down round feature adjustments related to preferred stock |
||||||||
|
Warrant liabilities transferred to equity |
||||||||
|
Derivative liability transferred to equity |
||||||||
|
Issuance of derivative liability in conjunction with Unsecured Convertible Notes |
||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
NOTE 1. ORGANIZATION
NovaBay Pharmaceuticals, Inc. (the “Company” or “our,” “we,” or “us”) was previously focused on the development and sale of eyecare, wound care, and skin care products. The Company may continue to manufacture wound care products domestically in the United States and export finished goods to China.
|
● |
The Avenova Asset Divestiture closed on January 17, 2025 in which we sold our primary eyecare business (see Note 14, “Avenova Asset Divestiture and Bridge Loan”); |
|
|
● |
The PhaseOne Divestiture closed on January 8, 2025 in which we sold our PhaseOne trademark (see Note 15, “PhaseOne Divestiture”); and |
|
|
● |
The DERMAdoctor Divestiture closed on March 12, 2024 in which we sold our primary skin care business (see Note 16, “DERMAdoctor Divestiture”). |
The Company was incorporated under the laws of the State of California on January 19, 2000, as NovaCal Pharmaceuticals, Inc. It had no operations until July 1, 2002, on which date it acquired all of the operating assets of NovaCal Pharmaceuticals, LLC, a California limited liability company. In February 2007, the Company changed its name from NovaCal Pharmaceuticals, Inc. to NovaBay Pharmaceuticals, Inc. In June 2010, the Company changed the state in which it was incorporated pursuant to the Reincorporation and is now incorporated under the laws of the State of Delaware. All references to “the Company” herein refer to the California corporation prior to the date of the Reincorporation and to the Delaware corporation on and after the date of the Reincorporation. The Company is managed as one reportable segment consisting of its ongoing wound care business.
On May 30, 2024, the Company effected the Reverse Stock Split. Except as otherwise specifically noted, all share numbers, share prices, exercise/conversion prices and per share amounts have been adjusted, on a retroactive basis, to reflect the Reverse Stock Split.
Discontinued Operations
Historical financial results related to each of the businesses and assets divested above are now presented as discontinued operations in our unaudited condensed consolidated financial statements (see Note 14, “Avenova Asset Divestiture and Bridge Loan”; Note 15, “PhaseOne Divestiture”; and Note 16, “DERMAdoctor Divestiture”).
Previous Plan of Dissolution and Strategic Direction of the Company
The Company’s board of directors (the “Board”) unanimously approved each of the divestitures above and subsequently evaluated additional strategic options available to the Company. During this time, the Board pursued a voluntary liquidation and dissolution under Delaware law (the “Dissolution”) pursuant to a Plan of Complete Liquidation and Dissolution (the “Plan of Dissolution”) which was approved at a special meeting of stockholders that was held on April 16, 2025 (the “2025 Special Meeting”). Although stockholder approval of the Dissolution was received, the Board was authorized to subsequently determine, in its discretion, whether or not to proceed with the Dissolution. The Board ultimately determined not to pursue the Dissolution and simultaneously entered into the 2025 Preferred Stock Purchase Agreement (see Note 8, “Financing Activities”), Series E Preferred Stock Closing (see Note 19, “Subsequent Events”) and October 2025 Pre-Funded Warrants (see Note 19, “Subsequent Events”). As part of its broader capital allocation review, the Company has begun evaluating opportunities within emerging financial infrastructure and network-based markets. These opportunities may include select blockchain-based assets that the Company believes could enhance capital efficiency and long-term stockholder value.
Liquidity
Based on our funds available on September 30, 2025, together with net proceeds from the issuance of the Series E Preferred Stock and October 2025 Pre-Funded Warrants (see Note 19, “Subsequent Events”), management believes that the Company’s existing cash and cash equivalents will be sufficient to enable the Company to meet its planned operating expenses at least through November 7, 2026; however, as referenced above, the Company is considering adjustments to its strategic direction. As a result of any change in the Company’s strategic direction, there may be circumstances that cause the Company to adjust its anticipated spending in the near term.
NOTE 2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) and are expressed in U.S. dollars. In management’s opinion, the unaudited condensed consolidated financial statements include all normal and recurring adjustments that are considered necessary for the fair presentation of the Company’s financial position and operating results.
Principles of Consolidation
The accompanying unaudited condensed consolidated financial statements include the accounts of the Company and its former wholly owned subsidiary, DERMAdoctor, which was fully divested on March 12, 2024, as of and for the nine months ended September 30, 2024. All significant intercompany balances and transactions have been eliminated in consolidation. See also Note 16, “DERMAdoctor Divestiture.” The accompanying unaudited condensed consolidated financial statements include only the accounts of the Company for the three and nine months ended September 30, 2025.
Financial Statement Reclassification
Certain account balances from prior periods have been reclassified in these unaudited condensed consolidated financial statements to conform to current period classifications. Prior year amounts have been modified in these unaudited condensed consolidated financial statements to properly report amounts under current operations and discontinued operations (see Note 14, “Avenova Asset Divestiture and Bridge Loan”; Note 15, “PhaseOne Divestiture”; and Note 16, “DERMAdoctor Divestiture”).
Use of Estimates
The preparation of financial statements in accordance with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in the unaudited condensed consolidated financial statements and accompanying notes. Actual results may differ significantly from those estimates. Significant estimates made by management include, but are not limited to, contract liabilities related to product sales such as product returns, assumptions for valuing warrants, assumptions for valuing derivative liabilities, long-lived asset impairments, stock-based compensation, income taxes and other contingencies.
These estimates are based on management’s best estimates and judgment. Actual results may differ from these estimates. Estimates, judgments, and assumptions are continuously evaluated and are based on management’s experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances. Uncertainty about these assumptions, judgments and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods.
Segment Information
The Company has one operating and reportable segment that encompasses the Company’s consolidated ongoing operations, reflecting the integrated nature of its currently limited business. The Company’s chief operating decision maker (“CODM”) is its chief executive officer. The measurement of profit and loss is the segment loss, which is equivalent to the “net loss from continuing operations” as reported on the Company's condensed consolidated statements of operations. The measurement of segment assets is reported on the Company’s condensed consolidated balance sheet as “total assets.” The CODM allocates resources to the Company’s initiatives and assesses performance on a consolidated basis, focused on the maintenance of the Company’s cash resources while assessing strategic alternatives on an ongoing basis and maintaining its public company status. The CODM is not regularly provided with disaggregated actual expense information, other than the actual expense information included in the condensed consolidated statements of operations, as the Company’s integrated operating model emphasizes shared resources and centralized decision-making.
Unaudited Condensed Consolidated Interim Financial Information
The accompanying unaudited condensed consolidated financial statements and related disclosures have been prepared on the same basis as the annual consolidated financial statements and, in the opinion of management, reflect all adjustments, which include only recurring adjustments, necessary for a fair presentation.
The year-end condensed consolidated balance sheet data was derived from the audited consolidated financial statements but does not include all disclosures required by U.S. GAAP. The unaudited condensed consolidated results of operations for any interim period are not necessarily indicative of the results to be expected for the full year or for any other future year or interim period.
The unaudited condensed consolidated financial statements and notes included herein should be read in conjunction with the annual consolidated financial statements and notes for the year ended December 31, 2024, included in the Company’s Annual Report on Form 10-K for the year ended December 31, 2024, which was filed with the SEC on April 2, 2025 (collectively, the “2024 Annual Report”).
Cash, Cash Equivalents, and Highly Liquid Restricted Cash
The Company considers all highly-liquid instruments with a stated maturity of three months or less at the date of purchase to be cash equivalents. Cash and cash equivalents are stated at cost, which approximates fair value. As of September 30, 2025 and December 31, 2024, the Company’s cash and cash equivalents were held in a major financial institution in the United States.
The following table provides a reconciliation of the cash, cash equivalents, and restricted cash reported in the condensed consolidated balance sheets (in thousands):
|
September 30, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
Cash and cash equivalents |
$ | $ | ||||||
|
Restricted cash included in other assets |
||||||||
|
Total cash, cash equivalents, and restricted cash in the condensed consolidated statements of cash flows |
$ | $ | ||||||
The restricted cash amount included in other assets on the condensed consolidated balance sheets represents amounts held as certificates of deposit for long-term financing and lease arrangements as contractually required by our financial institution and landlord.
Concentrations of Credit Risk and Major Partners
Financial instruments that potentially subject us to significant concentrations of credit risk consist primarily of cash, cash equivalents and restricted cash. The Company maintains deposits of cash, cash equivalents and restricted cash with a major financial institution in the United States.
The Company has a significant amount of its cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse impact on the Company’s financial condition, results of operations, and cash flows.
Fair Value of Financial Assets and Liabilities
The Company’s financial instruments include cash and cash equivalents, restricted cash, accounts payable, accrued liabilities and warrant liabilities. The Company’s cash and cash equivalents, restricted cash, accounts payable, and accrued liabilities are carried at cost, which management believes approximates fair value due to the short-term nature of these instruments.
The Company follows Accounting Standards Codification (“ASC”) 820, Fair Value Measurements and Disclosures, with respect to assets and liabilities that are measured at fair value on a recurring basis and nonrecurring basis. Under this standard, fair value is defined as the exit price, or the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants as of the measurement date. The standard also establishes a hierarchy for inputs used in measuring fair value that maximizes the use of observable inputs and minimizes the use of unobservable inputs by requiring that the most observable inputs be used when available. Observable inputs are inputs market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company’s assumptions about the factors market participants would use in valuing the asset or liability developed based upon the best information available in the circumstances. There are three levels of inputs that may be used to measure fair value:
Level 1 – quoted prices in active markets for identical assets or liabilities;
Level 2 – quoted prices for similar assets and liabilities in active markets or inputs that are observable; and
Level 3 – inputs that are unobservable (for example, cash flow modeling inputs based on assumptions).
Categorization within the valuation hierarchy is based upon the lowest level of input that is significant to the fair value measurement.
See additional information in Note 3, “Fair Value Measurements.”
Property and Equipment, Net
Property and equipment are stated at cost, less accumulated depreciation. Depreciation is calculated using the straight-line method over the estimated useful lives of the related assets of five to seven years for office and laboratory equipment, three to five years for computer equipment and software, and five to seven years for furniture and fixtures. Leasehold improvements are amortized over the shorter of the estimated useful life of the asset or the lease term.
The costs of normal maintenance, repairs, and minor replacements are expensed as incurred.
Impairment of Long-Lived Assets
The Company’s long-lived assets are reviewed for impairment in accordance with ASC 360, Property, Plant and Equipment, which requires that companies consider whether events or changes in facts and circumstances, both internally and externally, may indicate that an impairment of long-lived assets held for use are present. The Company reviews long-lived assets for impairment at least annually or whenever events or changes in business circumstances indicate that the carrying amount of the assets may not be fully recoverable or that the useful lives of these assets are no longer appropriate. Determination of recoverability is based on an estimate of undiscounted future cash flows resulting from the use of the asset and its eventual disposition. In the event that such cash flows are not expected to be sufficient to recover the carrying amount of the asset, the assets are written down to their estimated fair values and the loss is recognized in the condensed consolidated statements of operations. The Company recorded $
Leases
At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present. Operating lease liabilities and their corresponding right-of-use assets are recorded based on the present value of lease payments over the expected lease term. The interest rate implicit in lease contracts is typically not readily determinable. As such, the Company utilizes its incremental borrowing rate, which is the rate incurred to borrow, on a collateralized basis over a similar term, an amount equal to the lease payments in a similar economic environment. Certain adjustments to the right-of-use assets may be required for items such as initial direct costs paid or incentives received.
The Company has elected to combine lease and non-lease components as a single component. This will potentially result in the initial and subsequent measurement of the balances of the right-of-use assets and lease liability for leases being greater than if the policy election was not applied. Leases include variable components (e.g., common area maintenance) that are paid separately from the monthly base payment based on actual costs incurred and therefore were not included in the right-of-use assets and lease liability but are reflected as an expense in the period incurred.
The lease expense is recognized over the expected term on a straight-line basis. Operating leases are recognized in the condensed consolidated balance sheets as right-of-use assets, operating lease liabilities current and operating lease liabilities non-current.
The Company recorded $
Common Stock Warrants
The Company accounts for common stock purchase warrants issued in connection with its equity offerings in accordance with the provisions of ASC 480, Distinguishing Liabilities from Equity, and ASC 815, Derivatives and Hedging (ASC 815).
The Company classifies as equity any warrants that (i) require physical share settlement or net-share settlement or (ii) give the Company a choice of net-cash settlement (physical share settlement or net-share settlement). The Company classifies as liabilities any warrants that (i) require net-cash settlement, (ii) give the counterparty a choice of net-cash physical settlement or net-share settlement. In accordance with ASC 815, the Company also classifies as liabilities any warrants for which the shares underlying the contract are subject to stockholder approval before the warrant can be exercised.
For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the condensed consolidated statements of operations. The fair values of these warrants are determined using the Black-Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See Note 3, “Fair Value Measurements,” subheading “Black Scholes Valuation Models and Assumptions” and Note 10, “Common Stock Warrants.”
Amendments to warrant terms are recorded as a non-cash gain or loss on modification of common stock warrants. The gain or loss represents the decrease or increase in the fair value of the amended warrants when comparing the value immediately before and after amendment using the Black-Scholes option pricing model. See Note 3, “Fair Value Measurements,” subheading “Black Scholes Valuation Models and Assumptions.”
Preferred Stock
Preferred stock that is redeemable at the option of the holder or upon events not solely within the control of the Company is classified as mezzanine (temporary) equity in accordance with ASC 480-10-S99-3A. Such instruments are initially recorded at fair value, net of issuance costs, and are not accreted to redemption value unless redemption becomes probable.
Terms of the Company’s Preferred Stock have historically included a Ratchet whereby the applicable conversion price could be adjusted (as defined and described in Note 11, “Stockholders’ Equity (Deficit)”). The applicable Ratchet provisions of the Company’s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. Prior to a termination, when a conversion price for outstanding Preferred Stock was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, Fair Value Measurements and Disclosures (“ASC 820”), the deemed dividend was measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the Ratchet anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the Ratchet anti-dilution protection feature). These fair values were determined using the Black Scholes option pricing model. These values are subject to a significant degree of management’s judgment. See also Note 3, “Fair Value Measurements,” subheading “Black Scholes Valuation Models and Assumptions.”
Stock-Based Compensation
The Company’s stock-based compensation includes grants of stock options and restricted stock units (“RSUs”) to employees, consultants and non-employee directors. The expense associated with these grants is recognized in the Company’s condensed consolidated statements of operations based on their fair values as they are earned under the applicable vesting terms. For stock options granted, the fair value of the stock options is estimated using a Black-Scholes option pricing model. The Company accounts for RSUs issued to employees and non-employees (directors, consultants and advisory board members) based on the fair market value of the Company’s common stock on the date of issuance. See Note 12, “Stock-Based Compensation” for further information regarding stock-based compensation expense and the assumptions used in estimating the expense.
Income Taxes
The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and tax credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date. A valuation allowance is recognized if it is more likely than not that some portion or the entire deferred tax asset will not be recognized.
Net (Loss) Income per Share
The Company computes net (loss) income per share by presenting both basic and diluted loss per share (“EPS”) as shown in the Company’s condensed consolidated statements of operations (unaudited).
Basic EPS is computed by dividing net loss available to common stockholders by the weighted average number of common shares outstanding during the period. Diluted EPS gives effect to all dilutive potential common shares outstanding during the period, including stock options and warrants, using the treasury stock method. In computing diluted EPS, the average stock price for the period is used to determine the number of shares assumed to be purchased from the exercise of stock options or warrants. Potentially dilutive common share equivalents are excluded from the diluted EPS computation in net loss periods if their effect would be anti-dilutive.
The following table provides a reconciliation of the numerator and denominator used for basic and diluted (loss) earnings per share (in thousands):
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Numerator for basic and diluted income (loss) per share: |
||||||||||||||||
|
Net loss from continuing operations |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Less: Increase to accumulated deficit due to adjustment to common stock warrants exercise price |
||||||||||||||||
|
Less: Increase to accumulated deficit due to adjustment to Preferred Stock conversion price |
||||||||||||||||
|
Net loss from continuing operations attributable to common stockholders |
$ | ( |
) | $ | ( |
) | $ | ( |
) | $ | ( |
) | ||||
|
Net income from discontinued operations, net of taxes |
||||||||||||||||
|
Net (loss) income |
$ | ( |
) | $ | ( |
) | $ | $ | ( |
) | ||||||
|
Denominator for (loss) income per share: |
||||||||||||||||
|
Weighted average shares outstanding – basic (diluted for net loss) |
||||||||||||||||
|
Effect of dilutive Unsecured Convertible Notes |
||||||||||||||||
|
Weighted average shares outstanding – diluted for net income |
||||||||||||||||
The following outstanding preferred stock, stock options and stock warrants were excluded from the diluted EPS computation as their effect would have been anti-dilutive (in thousands):
|
As of September 30, |
||||||||
|
2025 |
2024 |
|||||||
|
Common stock equivalent of Series B Non-Voting Convertible Preferred Stock (the “Series B Preferred Stock”) |
||||||||
|
Stock options |
||||||||
|
Stock warrants |
||||||||
Recent Accounting Pronouncements
In November 2024, the FASB issued Accounting Standards Update (“ASU”) No. 2024-03, Disaggregation of Income Statement Expenses (“ASU 2024-03”). ASU 2024-03 is intended to increase transparency and provide investors with more detailed information about the nature of expenses reported on the face of the statements of operations. ASU 2024-03 does not change the requirements for the presentation of expenses on the face of the statements of operations. Under ASU 2024-03, entities are required to disaggregate, in tabular format, expenses presented on the face of the statements of operations if they include any of the following expense categories: employee compensation, depreciation, intangible asset amortization, and depreciation or depletion. For any remaining items within each relevant expense caption, entities must provide a qualitative description of the nature of those expenses. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026 and interim reporting periods beginning after December 15, 2027. Early adoption is permitted. While the adoption of ASU 2024-03 is not expected to have an effect on our consolidated financial statements, it is expected to result in incremental disclosures within the notes to our condensed consolidated financial statements. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s condensed consolidated financial statements.
For information regarding additional accounting pronouncements that could affect our business, results of operations, financial condition, and liquidity, see Note 2, “Summary of Significant Accounting Policies” included in our 2024 Annual Report. The Company continues to evaluate the potential impact of adopting the new accounting guidance on its consolidated financial position, results of operations and cash flows.
NOTE 3. FAIR VALUE MEASUREMENTS
The following tables present the Company’s financial instruments measured at fair value on a recurring basis as of September 30, 2025 and December 31, 2024 (in thousands):
|
Fair Value Measurements Using |
||||||||||||||||
|
Quoted |
||||||||||||||||
|
Prices in |
||||||||||||||||
|
Active |
||||||||||||||||
|
Markets |
Significant |
|||||||||||||||
| for |
Other |
Significant |
||||||||||||||
|
Balance at |
Identical |
Observable |
Unobservable |
|||||||||||||
|
September 30, |
Items |
Inputs |
Inputs |
|||||||||||||
|
2025 |
(Level 1) |
(Level 2) |
(Level 3) |
|||||||||||||
|
Assets |
||||||||||||||||
|
Restricted cash held as a deposit |
$ | $ | $ | $ | ||||||||||||
|
Fair Value Measurements Using |
||||||||||||||||
|
Quoted |
||||||||||||||||
|
Prices in |
||||||||||||||||
|
Active |
||||||||||||||||
|
Markets |
Significant |
|||||||||||||||
| for |
Other |
Significant |
||||||||||||||
|
Balance at |
Identical |
Observable |
Unobservable |
|||||||||||||
|
December 31, |
Items |
Inputs |
Inputs |
|||||||||||||
|
2024 |
(Level 1) |
(Level 2) |
(Level 3) |
|||||||||||||
|
Assets |
||||||||||||||||
|
Restricted cash held as a deposit |
$ | $ | $ | $ | ||||||||||||
The Company’s cash equivalents and restricted cash held as a deposit are classified within Level 1 of the fair value hierarchy because they are valued using quoted market prices in active markets, broker or dealer quotations, or alternative pricing sources with reasonable levels of price transparency.
Black Scholes Valuation Models and Assumptions
The Company utilizes a Black Scholes model for various valuations as outlined throughout this report. The following tables summarize the assumptions utilized for valuations impacting results for the periods reported. See also Note 12, “Stock-Based Compensation” for related Black Scholes valuation assumptions.
Warrant Liabilities
Certain of the Company’s warrants were subject to stockholder approval upon issuance or amendment and prior to exercise. Warrants requiring stockholder approval are recorded as a liability at fair value upon issuance or amendment and continue to be recorded as a liability at fair value at each reporting date until stockholder approval occurs at which time they are transferred to stockholders’ equity at their fair value on the date of approval. Fair value was determined using a Black Scholes model as outlined below. See Note 10, “Common Stock Warrants” for additional information and the definitions of the Company’s warrants.
|
December 2023 Warrants |
December 2023 Warrants |
|||||||
|
Measurement event |
Reporting Date |
Stockholder Approval |
||||||
|
Date |
December 31, 2023 |
May 28, 2024 |
||||||
|
Total Value (in millions) |
||||||||
|
Gain (Loss) (in thousands) |
not applicable |
( |
) | |||||
|
Assumptions: |
||||||||
|
Exercise price |
$ | $ | ||||||
|
Market price |
$ |
$ | ||||||
|
Volatility |
% | % | ||||||
|
Risk-free rate |
% | % | ||||||
|
Dividend yield |
% | % | ||||||
|
Term (years) |
||||||||
|
March |
March |
|||||||
|
2024 |
2024 |
|||||||
|
Warrant |
Warrant |
|||||||
|
Measurement event |
Issuance |
Stockholder Approval |
||||||
|
Date |
March 25, 2024 |
May 28, 2024 |
||||||
|
Total Value (in millions) |
$ | $ | ||||||
|
Gain (Loss) (in thousands) |
$ | ( |
) | |||||
|
Assumptions: |
||||||||
|
Exercise price |
$ | $ | ||||||
|
Market price |
$ | $ | ||||||
|
Volatility |
% | % | ||||||
|
Risk-free rate |
% | % | ||||||
|
Dividend yield |
% | % | ||||||
|
Term (years) |
||||||||
|
September 2022, November 2022, & May 2023 Warrants |
||||||||||||
|
Measurement event |
Prior to amendment |
After amendment |
||||||||||
|
Date |
June 14, 2024 |
June 14, 2024 |
||||||||||
|
Total Value (in thousands) |
$ | $ | ||||||||||
|
Loss (in thousands) |
not applicable |
$ | ||||||||||
|
Assumptions: |
||||||||||||
|
Exercise price |
$ | - | $ | |||||||||
|
Market price |
$ | $ | ||||||||||
|
Volatility |
% | % | ||||||||||
|
Risk-free rate |
- | - | ||||||||||
|
Dividend yield |
% | % | ||||||||||
|
Term (years) |
- | - | ||||||||||
Preferred Stock Conversion Price Adjustments
Terms of the Company’s outstanding Preferred Stock historically included a Ratchet whereby the applicable conversion price could be adjusted (see Note 11, “Stockholders’ Equity (Deficit)”). The applicable Ratchet provisions of the Company’s outstanding Preferred Stock terminated during the quarter ended March 31, 2024. Prior to its termination, when a conversion price for outstanding Preferred Stock was adjusted under the Ratchet, the Company recorded a deemed dividend as a reduction to income available to common stockholders. In accordance with ASC 820, the deemed dividend is measured as the difference between (1) the fair value of the Preferred Stock immediately prior to the conversion price adjustment (but without the Ratchet anti-dilution protection feature) and (2) the fair value of the Preferred Stock immediately after the conversion price adjustment (but without the Ratchet anti-dilution protection feature). Fair value was determined using a Black Scholes model as outlined below.
|
Series C Preferred Stock |
||||||||
|
Measurement event |
Prior to Ratchet |
After Ratchet |
||||||
|
Date |
March 24, 2024 |
March 24, 2024 |
||||||
|
Total value (a) (in millions) |
$ | $ | ||||||
|
Deemed dividend (in millions) |
not applicable |
$ | ||||||
|
Assumptions: |
||||||||
|
Exercise price |
$ | $ | ||||||
|
Market price |
$ | $ | ||||||
|
Volatility |
% | % | ||||||
|
Risk-free rate |
% | % | ||||||
|
Dividend yield |
% | % | ||||||
|
Term (in years) |
||||||||
|
(a) |
|
Bifurcatable Derivatives
Upon issuance in March 2024, the Unsecured Convertible Notes contained a lender’s conversion option which represented an embedded call option requiring bifurcation as an embedded derivative liability at fair value (see Note 9, “Convertible Notes” for additional discussion). Fair value was determined using a Black Scholes model as outlined below.
|
Unsecured Convertible Notes derivative |
Unsecured Convertible Notes derivative |
|||||||
|
Measurement event |
Issuance |
Stockholder Approval |
||||||
|
Date |
March 25, 2024 |
May 28, 2024 |
||||||
|
Total value (in millions) |
$ | $ | ||||||
|
Gain (Loss) (in thousands) |
not applicable |
$ | ( |
) | ||||
|
Assumptions: |
||||||||
|
Exercise price |
$ | $ | ||||||
|
Market price |
$ | $ | ||||||
|
Volatility |
% | % | ||||||
|
Risk-free rate |
% | % | ||||||
|
Dividend yield |
% | % | ||||||
|
Term (years) |
||||||||
NOTE 4. PREPAID EXPENSES AND OTHER CURRENT ASSETS
Prepaid expenses and other current assets consisted of the following (in thousands):
|
September 30, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
Series E Preferred Stock deferred financing costs |
$ | $ | ||||||
|
Dues & subscriptions |
||||||||
|
Prepaid taxes & licenses |
||||||||
|
Prepaid insurance |
||||||||
|
Other receivables |
||||||||
|
Other |
||||||||
|
Total prepaid expenses and other current assets |
$ | $ | ||||||
NOTE 5. PROPERTY AND EQUIPMENT
Property and equipment consisted of the following (in thousands):
|
September 30, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
Office and laboratory equipment |
$ | $ | ||||||
|
Furniture and fixtures |
||||||||
|
Computer equipment and software |
||||||||
|
Leasehold improvements |
||||||||
|
Total property and equipment, at cost |
||||||||
|
Less: Impairments |
( |
) | ||||||
|
Less: Accumulated depreciation |
( |
) | ( |
) | ||||
|
Total property and equipment, net |
$ | $ | ||||||
Depreciation expense related to continuing operations was $
The Company disposed of damaged, unusable and fully depreciated property and equipment with a cost of approximately $
Additionally, the Company impaired $
NOTE 6. ACCRUED LIABILITIES
Accrued liabilities consisted of the following (in thousands):
|
September 30, |
December 31, |
|||||||
|
2025 |
2024 |
|||||||
|
Employee payroll and benefits |
$ | $ | ||||||
|
Income taxes |
||||||||
|
Interest |
||||||||
|
Professional services |
||||||||
|
Other |
||||||||
|
Total accrued liabilities |
$ | $ | ||||||
NOTE 7. COMMITMENTS AND CONTINGENCIES
As permitted under Delaware law and in accordance with its bylaws, the Company indemnifies its officers and directors for certain events or occurrences while the officer or director is or was serving at the Company’s request in such capacity. The term of the indemnification period is for the officer’s or director’s lifetime. The maximum amount of potential future indemnification is unlimited; however, the Company has a director and officer insurance policy that limits its exposure and may enable it to recover a portion of any future payments. The Company believes the fair value of these indemnification agreements is minimal. Accordingly, it has not recorded any liabilities for these agreements as of September 30, 2025 or December 31, 2024.
In the normal course of business, the Company provides indemnification of varying scope under its agreements with other entities, typically its suppliers and others, including in connection with capital raises transactions. Additionally, the Company provided for certain indemnification in conjunction with the Avenova Asset Divestiture (see Note 14, “Avenova Asset Divestiture and Bridge Loan”). Pursuant to these agreements, it generally indemnifies, holds harmless, and agrees to reimburse the indemnified parties for losses suffered or incurred by the indemnified parties in connection with the use or testing of its products or product candidates or with any U.S. patent or any copyright or other intellectual property infringement claims by any third party with respect to its products. The term of these indemnification agreements is generally perpetual. The potential future payments the Company could be required to make under these indemnification agreements are unlimited. Historically, costs related to these indemnification provisions have been immaterial. The Company also maintains various liability insurance policies that limit its exposure. As a result, it believes the fair value of these indemnification agreements is minimal. Accordingly, the Company has not recorded any liabilities for these agreements as of September 30, 2025 or December 31, 2024.
Legal Matters
From time to time, the Company is subject to various legal proceedings, as well as demands, claims and threatened litigation, which arise in the normal course of our business. The ultimate outcome of any litigation or other legal dispute is uncertain. When a loss related to a legal proceeding or claim is probable and reasonably estimable, the Company accrues its best estimate for the ultimate resolution of the matter. If one or more legal matters are resolved against the Company in a reporting period for an amount above expectations, the Company’s financial condition and operating results for that period may be adversely affected. As of September 30, 2025 and December 31, 2024, there were no legal matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Company’s financial position, results of operations or cash flows. Any outcome, whether favorable or unfavorable, may materially and adversely affect the Company due to legal costs and expenses, diversion of management attention and other factors. The Company cannot provide assurance that additional contingencies of a legal nature or contingencies having legal aspects will not be asserted against it in the future, and these matters could relate to prior, current, or future transactions or events.
Leases
The Company leases office space for its corporate headquarters located in Emeryville, California. The current lease term expires on July 31, 2027. The Company recorded $
Lease costs for the three and nine months ended September 30, 2025 and 2024 were as follows (in thousands):
|
For the Three Months Ended September 30, |
For the Nine Months Ended September 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Operating lease – expense |
$ | $ | $ | $ | ||||||||||||
|
Operating lease – included in operating cash flow |
||||||||||||||||
The Company has measured its operating lease liabilities as the present value of minimum lease payments using its incremental borrowing rate over the remaining term for each operating lease. The weighted average remaining lease term and the weighted average discount rate for operating leases from continuing operations are summarized as follows:
|
September 30, 2025 |
September 30, 2024 |
|||||||
|
Weighted-average remaining lease term (in years) |
||||||||
|
Weighted-average discount rate |
% | % | ||||||
Future lease payments under non-cancelable leases as of September 30, 2025 were as follows (in thousands):
|
2025 |
$ | |||
|
2026 |
||||
|
2027 |
||||
|
Total future minimum lease payments |
||||
|
Less: Imputed interest |
( |
) | ||
|
Total |
$ | |||
|
Reported as: |
||||
|
Operating lease liability |
$ | |||
|
Operating lease liability- non-current |
||||
|
Total |
$ |
NOTE 8. FINANCING ACTIVITIES
See Notes 2, “Summary of Significant Accounting Policies;” 3, “Fair Value Measurements;” 9, “Convertible Notes;” 10, “Common Stock Warrants” and 11, “Stockholders’ Equity (Deficit)” for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates.
2025 Preferred Stock Purchase Agreement
On August 19, 2025, the Company entered into a securities purchase agreement (the “2025 Preferred Stock Purchase Agreement”) with David E. Lazar, that provides for the Company to sell in a private placement (i) an aggregate of
Simultaneous to entering into the 2025 Preferred Stock Purchase Agreement on August 19, 2025, Mr. Lazar completed the purchase of the
Since the Common Stock is currently listed on the NYSE American, LLC (“NYSE American”), and among these requirements are Section 713(a) and (b) of the NYSE American Company Guide (the “Company Guide”). Section 713(a) of the Company Guide requires stockholder approval in connection with any transaction, other than a public offering, involving the sale, issuance, or potential issuance, of common stock or securities convertible into common stock, equal to 20.0% or more of presently outstanding stock for less than the greater of book or market value. Section 713(b) of the Company Guide requires stockholder approval of a transaction, other than a public offering, involving the sale, issuance or potential issuance by an issuer of common stock (or securities convertible into, or exercisable for, common stock) when the issuance or potential issuance of additional shares may result in a change of control of the issuer. As a result of the significant number of shares of Common Stock that may be issued upon the future conversion of the Series D Preferred Stock and Series E Preferred Stock compared to the currently issued and outstanding shares of Common Stock as provided above, the Company was required to obtain stockholder approval in accordance with the Company Guide Rule 713(a) and Rule 713(b) for Mr. Lazar to be able to convert the Series D Preferred Stock and the Series E Preferred Stock (the “Conversion Approval”).
Conversion Approval was obtained subsequent to September 30, 2025, on October 16, 2025. See additional discussion in Note 19, “Subsequent Events”.
On October 16, 2025, subsequent to September 30, 2025 and the Conversion Approval, the Company completed the sale of
2025 Warrant Exchange and Issuance of Series F Preferred Stock
On August 19, 2025, simultaneous with the signing of the 2025 Preferred Stock Purchase Agreement, the Company entered into warrant exchange agreements (the “Series F Agreements”) with each of Anson Investments Master Fund LP, Hudson Bay Capital Management LP and Armistice Capital, LLC (collectively, the “Series F Holders”). The Series F Agreements provide for the irrevocable surrender and cancellation of all warrants beneficially owned by the Series F Holders, in exchange for the Company issuing (i) an aggregate of
Because the carrying value of the Common Stock Warrants cancelled in conjunction with the Series F Agreements exceeded the total cash payment made and carry value of the Series F Preferred Stock issued, the Company recorded a deemed capital contribution of $
2024 Public Offering
On July 26, 2024, the Company entered into an underwriting agreement (the “Underwriting Agreement”) with Ladenburg Thalmann & Co., Inc., as the sole underwriter (the “Underwriter”), relating to the issuance and sale in a public offering (the “2024 Public Offering”) of (i)
The Series F-1 Warrants had an exercise price of $
The July 2024 Warrants included a one-time down round feature adjustment where the exercise price was automatically reset to a price equal to the lesser of (i) the then exercise price and (ii)
The exercise price and number of shares of common stock issuable upon exercise of the July 2024 Warrants is subject to appropriate adjustment in the event of stock dividends, stock splits, reorganizations or similar events affecting the common stock and the exercise price. Subject to limited exceptions, a holder may not exercise any portion of its July 2024 Warrants to the extent that the holder would beneficially own more than
In addition, the Company granted the Underwriter a
The Underwriter partially exercised this option on July 26, 2024, for (i)
The 2024 Public Offering closed on July 29, 2024, and the Company received gross proceeds of $
2024 Warrant Reprice Transaction
In June 2024, the Company entered into a warrant reprice transaction (the “2024 Warrant Reprice Transaction”) with certain existing holders of (i) warrants issued in September 2022 to purchase common stock, (ii) Series A-1 Warrants issued in November 2022 to purchase common stock, (iii) Series B-1 Warrants issued in May 2023 to purchase common stock, and (iv) Series B-2 Warrants issued in May 2023 to purchase common stock (collectively (i) through (iv), the “Participant Warrants”). The participants agreed to exercise a portion of their Participant Warrants at a reduced exercise price of $
The Company also issued participants in the 2024 Warrant Reprice Transaction a new June 2024 Warrant to purchase a number of shares of common stock equal to 100% of the shares of common stock exercised. The June 2024 Warrants are substantially similar to the Participant Warrants, except that the June 2024 Warrants will (i) be initially exercisable on the six-month anniversary of the date of issuance; (ii) have an exercise price of $
The Company incurred total issuance costs of $
NOTE 9. CONVERTIBLE NOTES
Unsecured Convertible Notes
On March 24, 2024, in connection with completing certain required conditions to close the DERMAdoctor Divestiture, the Company and the holders of the Secured Convertible Notes (as defined below) entered into a First Amendment (the “First Amendment”) to the Company’s Security Agreement, dated April 27, 2023 (the “Security Agreement”), to remove all of the DERMAdoctor membership units and any assets of DERMAdoctor as collateral for the Company’s obligations pursuant to the Secured Convertible Notes and for DERMAdoctor to be removed as a party to the Security Agreement, and a Consent and Release (the “Subsidiary Guarantee Consent”), to terminate the Subsidiary Guarantee, dated April 7, 2023 (the “Subsidiary Guarantee”) (collectively, the “2024 Subsidiary Guarantee Termination”).
The Company issued $
The Unsecured Convertible Notes may be converted or redeemed for a conversion price equal to $
Upon issuance in March 2024, the lender’s conversion option under the Unsecured Convertible Notes represented an embedded call option requiring bifurcation as an embedded derivative liability because the common stock underlying the option required stockholder approval before the option could be exercised. The fair value of the embedded derivative was determined to be $
Assumptions.”
The discount to the note recorded for the embedded derivative liability upon issuance and debt issuance costs are being amortized to interest expense using the effective interest rate method over the term of the Unsecured Convertible Notes, assuming that the Unsecured Convertible Notes will be redeemed for cash of $
Secured Convertible Notes
In May 2023, the Company issued $
Beginning June 1, 2023, the Company was required to start making a monthly redemption of 1/18th of the original principal amount of the Secured Convertible Notes. Each monthly redemption reduced the outstanding principle of the Secured Convertible Note by $
The Secured Convertible Notes also provided for a redemption equal to up to
The discounts and debt issuance costs were amortized to interest expense using the effective interest rate method over the term of the Secured Convertible Notes. The effective interest rate on the Secured Convertible Notes was
NOTE 10. COMMON STOCK WARRANTS
See Notes 2, “Summary of Significant Accounting Policies;” 3, “Fair Value Measurements;” 8, “Financing Activities;” and 11, “Stockholders’ Equity (Deficit)” for certain defined terms below and additional discussion of financing activities and related accounting policies and fair value estimates.
July 2024 Pre-Funded Warrants
In July 2024, in conjunction with the 2024 Public Offering, the Company issued
During the third quarter of 2024, all of the July 2024 Pre-Funded Warrants had been exercised, resulting in the Company issuing
July 2024 Warrants
In July 2024, in conjunction with the 2024 Public Offering, the Company issued new July 2024 Warrants.
|
● |
Series F-1 Warrants exercisable for |
|
● |
Series F-2 Warrants exercisable for |
|
● |
Series F-3 Warrants exercisable for |
The July 2024 Warrants were classified as a component of permanent equity. The July 2024 Warrants down round feature adjustment was triggered on September 27, 2024, resulting in a reduced exercise price of $
In January 2025, Series F-2 Warrants were exercised for
In March 2025, the Company entered into three (3) separate confidential settlement and release agreements (collectively, the “Settlement Agreements”) with each of Sabby Volatility Warrant Master Fund, Ltd. (“Sabby”), Bigger Capital Fund, LP (“Bigger”) and District 2 Capital Fund LP (“District 2,” and together with Sabby and Bigger, the “Warrant Holders”) to settle certain disputed matters relating to the July 2024 Warrants held by each of the Warrant Holders. In connection with the Settlement Agreements, Series F-3 Warrants were exercised for
The Settlement Agreements include a “most favored nations” provision for each of the Warrant Holders that would increase the amount paid to the Warrant Holders if any other holder of the Company’s common stock receives a higher amount per underlying warrant, as well as a mutual release of all claims by the Company and the Warrant Holders against each other, without any admission of liability by either party. For more information on the Settlement Agreements, please see the Company’s Form 8-K filed on March 11, 2025.
During the quarter ended June 30, 2025, the Company repurchased Series F-1 Warrants exercisable for
In July 2025, Series F-3 Warrants were exercised for
On August 19, 2025, Series F-1 Warrants exercisable for
During the quarter ended September 30, 2025, Series F-1 Warrants were exercised for
June 2024 Warrants
In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company issued new common stock purchase warrants (the “June 2024 Warrants”) exercisable for
On August 19, 2025, June 2024 Warrants exercisable for
During the quarter ended September 30, 2025, June 2024 Warrants were exercised for
March 2024 Warrant
In March 2024, the Company executed the First Amendment and Subsidiary Guarantee Consent as part of the 2024 Subsidiary Guarantee Termination with holders of the Secured Convertible Notes (see Note 9, “Convertible Notes”) in order to satisfy a closing condition for the DERMAdoctor Divestiture (see Note 16, “DERMAdoctor Divestiture”). In exchange for the consent of each holder, the option, at the holder’s election, to receive upon the closing of the DERMAdoctor Divestiture either, a new common stock warrant (the “March 2024 Warrant”), or a new unsecured convertible note (see Note 9, “Convertible Notes”). One holder elected the option to receive a March 2024 Warrant exercisable for
The March 2024 Warrant was initially classified as a liability from the date of issuance until Company stockholder approval on May 28, 2024, at which time it was reclassified to equity.
On August 19, 2025, all remaining March 2024 Warrants exercisable for
December 2023 Warrants
In December 2023, the Company issued new common stock purchase warrants (the “December 2023 Warrants”) exercisable for
The December 2023 Warrants were initially classified as liabilities from the date of issuance until Company stockholder approval was received on May 28, 2024, at which time it was reclassified to equity.
On August 19, 2025, December 2023 Warrants exercisable for
May 2023 Warrants
In May 2023, the Company issued the following new common stock purchase warrants (collectively, the “May 2023 Warrants”):
|
● |
May 2023 Series B-1 Warrants exercisable for |
|
|
● |
May 2023 Series B-2 Warrants exercisable for |
In December 2023, the Company amended certain May 2023 Warrants to reduce their exercise prices to $
|
● |
May 2023 B-1 Warrants exercisable for |
|
|
● |
May 2023 B-2 Warrants exercisable for |
In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain May 2023 Warrants to reduce their exercise prices to $
|
● |
May 2023 B-1 Warrants exercisable for |
|
|
● |
May 2023 B-2 Warrants exercisable for |
November 2022 Warrants
In November 2022, the Company issued the following common stock purchase warrants (collectively, the “November 2022 Warrants”):
|
● |
November 2022 Series A-1 Warrants exercisable for |
|
|
● |
November 2022 Series A-2 Warrants exercisable for |
In May 2023, the Company amended certain November 2022 Warrants to reduce their exercise prices from $
|
● |
November 2022 A-1 Warrants exercisable for |
|
|
● |
November 2022 A-2 Warrants exercisable for |
In May 2024, all November 2022 Series A-2 Warrants for
In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain November 2022 Warrants to reduce their exercise prices from $
|
● |
November 2022 A-1 Warrants exercisable for |
September 2022 Warrants
In September 2022, the Company issued new common stock purchase warrants (the “September 2022 Warrants”) exercisable for
In May 2023, the Company amended certain September 2022 Warrants exercisable for
In June 2024, in conjunction with the 2024 Warrant Reprice Transaction, the Company amended certain September 2022 Warrants exercisable for
On August 19, 2025, September 2022 Warrants exercisable for
November 2021 Warrants
In November 2021, the Company issued new common stock purchase warrants (the “November 2021 Warrants”) exercisable for
In September 2022, the Company amended all November 2021 Warrants to reduce their exercise prices from $
In May 2023, the Company amended certain November 2021 Warrants exercisable for
On August 19, 2025, November 2021 Warrants exercisable for
July 2020 Warrants
In July 2020, the Company issued new common stock purchase warrants (the “July 2020 Warrants”) exercisable for
In September 2022, the Company amended certain July 2020 Warrants exercisable for
In May 2023, in conjunction with the 2023 Private Placement, the Company amended certain July 2020 Warrants exercisable for
Summary of Common Stock Warrant Activity and Outstanding
Activity related to common stock warrants outstanding at September 30, 2025 and 2024 were as follows:
|
Warrants |
Weighted- Average Exercise Price |
|||||||
|
Outstanding at December 31, 2023 |
$ | |||||||
|
Warrants granted |
||||||||
|
Warrants exercised |
||||||||
|
Warrants expired |
||||||||
|
Outstanding at September 30, 2024 |
||||||||
|
Outstanding at December 31, 2024 |
$ | |||||||
|
Warrants granted |
||||||||
|
Warrants exercised |
( |
) | ||||||
|
Warrants expired |
( |
) | ||||||
|
Warrants surrendered and cancelled |
( |
) | ||||||
|
Warrants repurchased |
( |
) | ||||||
|
Outstanding at September 30, 2025 |
||||||||
The surrender and cancellation of
The exercise of
Common stock warrants outstanding as of September 30, 2025 were as follows:
|
Series |
Exercise Price |
Expiration Date |
Warrants |
||||||
|
July 2020 Warrants |
$ |
|
|||||||
|
July 2020 Warrants |
|
||||||||
|
TLF Warrants |
|
||||||||
|
November 2021 Warrants |
|
||||||||
|
November 2021 Warrants |
|
||||||||
|
September 2022 Warrants |
|
||||||||
|
November 2022 A-1 Warrants |
|
||||||||
|
December 2023 Warrants |
|
||||||||
|
June 2024 Warrants |
|
||||||||
|
July 2024 F-1 Warrants |
|
||||||||
|
Outstanding at September 30, 2025 |
|||||||||
Summary of Common Stock Warrant Liabilities
The following is a reconciliation of the beginning and ending balances for warrant liabilities measured at fair value on a recurring basis (in thousands) during the period ended September 30, 2024. There were no warrant liabilities outstanding during the period ended September 30, 2025. See additional information per Note 3, “Fair Value Measurements,” subheading “Black Scholes Valuation Models and Assumptions.”
|
Warrant liabilities as of December 31, 2023 |
$ | |||
|
Decrease in fair value of December 2023 Warrants liability during period |
( |
) | ||
|
Fair value of March 2024 Warrant upon issuance |
||||
|
Increase in fair value of March 2024 Warrant liability during period |
||||
|
Reclassification of December 2023 Warrant liability to equity during period |
( |
) | ||
|
Reclassification of March 2024 Warrant liability to equity during period |
( |
) | ||
|
Warrant liabilities as of September 30, 2024 |
$ |
NOTE 11. STOCKHOLDERS’ EQUITY (DEFICIT)
Authorized Share Capital
Under the Company’s Amended and Restated Certificate of Incorporation, as amended, the Company is authorized to issue up to
Subsequent to September 30, 2025, on October 16, 2025, the Company filed a Certificate of Amendment to its Amended and Restated Certificate of Incorporation with the Secretary of State of the State of Delaware, which became effective upon filing. The amendment was approved by the Board and subsequently approved by the Company’s stockholders at the Annual Meeting of Stockholders held on October 16, 2025. The Certificate of Amendment provides that the Company is then authorized to issue an increased total of
Preferred Stock
There were two series of preferred stock of the Company outstanding during the nine months ended September 30, 2025 – the Series B Non-Voting Convertible Preferred Stock (“Series B Preferred Stock”) and the Series D Non-Voting Convertible Preferred Stock (“Series D Preferred Stock”). The rights and preferences of each are described below.
Series B Preferred Stock
The Company issued
The Series B Preferred Stock does not have any preemptive rights or a preference upon any liquidation, dissolution or winding-up of the Company. Each share of Series B Preferred Stock is convertible into $
Series C Preferred Stock
The Company issued
Series D Preferred Stock
The Company issued
Subsequent to September 30, 2025, on October 21, 2025, three business days after the Stockholder Approval, each share of Series D Preferred Stock automatically converted into
Series E Preferred Stock
On August 19, 2025, in connection with the 2025 Preferred Stock Purchase Agreement (see Note 8, “Financing Activities”), an investor committed to purchase shares of Series E Preferred Stock convertible into an aggregate of
Subsequent to September 30, 2025, on October 16, 2025, the Company issued
Series F Preferred Stock
The Company issued
The Series F Preferred Stock is not convertible into Common Stock or any other equity instrument and has no dividend rights. The Series F Preferred Stock has voting rights similar to Common Stock with each share of Series F Preferred Stock representing the voting equivalent of approximately
Upon issuance, the Series F Preferred Stock was not mandatorily redeemable because redemption was subject to Conversion Approval, and eventual redemption is at the option of the holders upon the occurrence of certain events that are not solely within the control of the Company. In accordance with ASC 480-10-S99-3A, although the Series F Preferred Stock is legally designated as equity and is not mandatorily redeemable, it does not meet the requirements for permanent equity classification upon issuance. Accordingly, the Series F Preferred Stock has been presented as mezzanine equity (temporary equity) on the Company’s condensed consolidated balance sheet, between liabilities and stockholders’ equity, at its initial carrying amount of $
Common Stock
See Notes 8, “Financing Activities” and 10, “Common Stock Warrants” for a description of common stock and common stock warrant-related transactions during the three and nine months ended September 30, 2025 and 2024.
Dividends
On August 26, 2025, the Special Transaction Committee of the Board of Director and the Company’s Board of Directors declared a special cash dividend of $
NOTE 12. STOCK-BASED COMPENSATION
Equity Compensation Plans
In October 2007, the Company adopted the 2007 Omnibus Incentive Plan (the “2007 Plan”) to provide for the grant of equity awards, such as stock options, unrestricted and restricted common stock, stock units, dividend equivalent rights, and stock appreciation rights to employees, directors and outside consultants, as determined by the Board. The 2007 Plan expired on March 15, 2017. Upon expiration, new awards cannot be issued pursuant to the 2007 Plan, but outstanding awards continue to be governed by its terms. Stock options granted under the 2007 Plan expire no later than ten years from the date of grant. All stock options outstanding under the 2007 Plan were fully vested as of December 31, 2024.
In March 2017, the Company adopted the 2017 Omnibus Incentive Plan (the “2017 Plan”), which was approved by stockholders on June 2, 2017, to provide for the grant of equity awards, such as nonqualified stock options (“NQSOs”), incentive stock options (“ISOs”), restricted stock, performance shares, stock appreciation rights (“SARs”), RSUs and other share-based awards to employees, directors, and consultants, as determined by the Board. The 2017 Plan does not affect awards previously granted under the 2007 Plan. Upon adoption, the 2017 Plan allowed for awards of up to
Under the terms of the 2017 Plan, the exercise price of NQSOs, ISOs and SARs may not be less than
Summary of Outstanding Equity Awards
The following table summarizes information about the Company’s stock options and restricted stock outstanding at December 31, 2024, and activity during the nine months ended September 30, 2025:
|
(in thousands, except years |
Awards |
Weighted- Average Exercise Price |
Weighted- Average Remaining Contractual Life (years) |
Aggregate Intrinsic Value |
||||||||||||
|
Outstanding at December 31, 2024 |
$ | $ | ||||||||||||||
|
Restricted stock units vested |
( |
) | ||||||||||||||
|
Options forfeited/cancelled |
( |
) | ||||||||||||||
|
Outstanding at September 30, 2025 |
||||||||||||||||
|
Vested and expected to vest at September 30, 2025 |
||||||||||||||||
|
Vested and exercisable at September 30, 2025 |
— | |||||||||||||||
The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying stock option awards and the closing market price of the Company’s common stock as quoted on the NYSE American as of September 30, 2025 for option awards that have an exercise price that is lower than the market price. There were no stock option awards exercised during the three and nine months ended September 30, 2025 and 2024.
As of September 30, 2025, there was no unrecognized compensation cost related to unvested stock options and restricted stock.
Equity Awards to Employees and Directors
The Company grants options to purchase common stock to its employees and directors at prices equal to or greater than the market value of the stock on the dates the options are granted. The Company has estimated the value of stock option awards as of the date of grant by applying the Black-Scholes option pricing model using the single-option valuation approach. The application of this valuation model involves assumptions that are judgmental and subjective in nature. See Note 2, “Summary of Significant Accounting Policies,” for a description of the accounting policies that the Company applied to value its stock-based awards.
The Company did not grant any stock options or shares of restricted stock to employees or directors to purchase shares of the Company’s common stock during the three and nine months ended September 30, 2025. During the nine months ended September 30, 2024, the Company granted
For the three months ended September 30, 2025 and 2024, the Company recognized stock-based compensation expense of $
Stock-Based Awards to Non-Employees
During the three and nine months ended September 30, 2025 and 2024, the Company did not grant options or restricted stock to non-employees in exchange for advisory and consulting services. The Company recognized stock-based compensation expense of $
Summary of Stock-Based Compensation Expense
A summary of the stock-based compensation expense included in results of continuing operations for the options and restricted stock awards discussed above is as follows (in thousands):
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
General and administrative |
$ | $ | $ | $ | ||||||||||||
NOTE 13. EMPLOYEE BENEFIT PLAN
The Company has a 401(k) plan covering all eligible employees. The Company provides matching contributions equal to
NOTE 14. AVENOVA ASSET DIVESTITURE AND BRIDGE LOAN
On January 17, 2025, the Company completed the sale of its eyecare products sold under the Avenova brand and related assets (the “Avenova Assets”) to PRN Physician Recommended Nutriceuticals, LLC, a Delaware limited liability company (“PRN”), which constituted substantially all of the Company’s revenue generating and operating assets (the “Avenova Asset Divestiture”). The Avenova Asset Divestiture was consummated pursuant to the Asset Purchase Agreement, dated September 19, 2024, as amended by Amendment No. 1 to the Asset Purchase Agreement, dated November 5, 2024 (as so amended, the “Purchase Agreement”). The Purchase Agreement provided for, among other terms, a base purchase price of $
In accordance with the Purchase Agreement, at the closing of the Avenova Asset Divestiture the Company received the cash purchase price equal to $
In connection with the closing of the Avenova Asset Divestiture on January 17, 2025, the Company entered into a Transition Services Agreement, dated January 17, 2025 with PRN, pursuant to which the Company agreed to provide services to PRN with respect to specified accounting, marketing, sales, customer service, regulatory and operational support for a period of four (
The accounting requirements for reporting results related to the Avenova Assets as discontinued operations were met during the first quarter of 2025. Accordingly, the unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements reflect the results related to the Avenova Assets as a discontinued operation for the periods presented.
In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of the discontinued operations in the condensed consolidated balance sheets. The assets and liabilities related to the Avenova Assets have been reflected as discontinued operations in the condensed consolidated balance sheets as of December 31, 2024, and consist of the following (in thousands):
|
Balance at December 31, 2024 |
||||
|
ASSETS |
||||
|
Current assets: |
||||
|
Accounts receivable, net |
$ | |||
|
Inventory, net |
||||
|
Prepaid expenses and other current assets |
||||
|
Total current assets, discontinued operations |
||||
|
Property and equipment, net, discontinued operations |
||||
|
Total assets, discontinued operations |
$ | |||
|
LIABILITIES |
||||
|
Liabilities: |
||||
|
Current liabilities: |
||||
|
Accounts payable |
$ | |||
|
Accrued liabilities |
||||
|
Total current liabilities, discontinued operations |
$ | |||
In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the condensed consolidated statements of operations. Results related to the Avenova Asset for the three and nine months ended September 30, 2025 and 2024 have been reflected as discontinued operations in the condensed consolidated statements of operations and consist of the following (in thousands):
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Net sales |
$ | $ | $ | $ | ||||||||||||
|
Cost of goods sold |
||||||||||||||||
|
Gross profit |
||||||||||||||||
|
Operating expenses: |
||||||||||||||||
|
Sales and marketing |
||||||||||||||||
|
Total operating expenses |
||||||||||||||||
|
Operating income |
||||||||||||||||
|
Gain on divestiture |
||||||||||||||||
|
Net income from discontinued operations before income taxes |
||||||||||||||||
|
(Benefit) Provision for income taxes |
( |
) | ||||||||||||||
|
Net income from discontinued operations, net of taxes |
$ | $ | $ | $ | ||||||||||||
In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the condensed consolidated statements of cash flows. Results related to the Avenova Asset for the nine months ended September 30, 2025 and 2024 have been reflected as discontinued operations in the condensed consolidated statements of cash flows and consist of the following (in thousands):
|
Nine Months Ended September 30, |
||||||||
|
2025 |
2024 |
|||||||
|
Operating activities: |
||||||||
|
Net income from discontinued operations, net of taxes |
$ | $ | ||||||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
|
Non-cash gain on divestiture |
( |
) | ||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
( |
) | ( |
) | ||||
|
Inventory |
||||||||
|
Prepaid expenses and other current assets |
( |
) | ||||||
|
Other assets |
||||||||
|
Accounts payable and accrued liabilities |
( |
) | ||||||
|
Net cash (used in) provided by operating activities, discontinued operations |
( |
) | ||||||
|
Investing activities: |
||||||||
|
Proceeds from divestiture |
||||||||
|
Net cash provided by investing activities, discontinued operations |
||||||||
|
Net increase in cash and cash equivalents, discontinued operations |
$ | $ | ||||||
NOTE 15. PHASEONE DIVESTITURE
On January 3, 2025, the Company entered into a Trademark Acquisition Agreement with its distributor, PhaseOne Health LLC (“PhaseOne”), that provided for the purchase by PhaseOne of two of the Company’s wound care trademarks (the “Wound Care Trademarks”) for a purchase price of $
The accounting requirements for reporting results related to the Wound Care Trademarks as discontinued operations were met during the first quarter of 2025. Accordingly, the unaudited condensed consolidated financial statements and notes to the unaudited condensed consolidated financial statements reflect the results related to the Wound Care Trademarks as a discontinued operation for the years presented.
In accordance with the provisions of ASC 205-20, the Company has separately reported the assets and liabilities of discontinued operations in the condensed consolidated balance sheets. The assets and liabilities related to the Wound Care Trademarks have been reflected as discontinued operations in the condensed consolidated balance sheets as of December 31, 2024, and consist of the following (in thousands):
|
Balance at December 31, 2024 |
||||
|
ASSETS |
||||
|
Current assets: |
||||
|
Accounts receivable, net |
$ | |||
|
Inventory, net |
||||
|
Total current assets, discontinued operations |
$ | |||
|
LIABILITIES |
||||
|
Liabilities: |
||||
|
Current liabilities: |
||||
|
Accounts payable |
$ | |||
|
Total current liabilities, discontinued operations |
$ | |||
In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the condensed consolidated statements of operations. Results related to the Wound Care Trademarks for the three and nine months ended September 30, 2025 and 2024 have been reflected as discontinued operations in the condensed consolidated statements of operations and consist of the following (in thousands):
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Net sales |
$ | $ | $ | $ | ||||||||||||
|
Cost of goods sold |
||||||||||||||||
|
Gross profit |
( |
) | ||||||||||||||
|
Operating expenses: |
||||||||||||||||
|
Research and development |
||||||||||||||||
|
Total operating expenses |
||||||||||||||||
|
Operating (loss) income |
( |
) | ||||||||||||||
|
Gain on divestiture |
||||||||||||||||
|
Net (loss) income from discontinued operations before income taxes |
( |
) | ||||||||||||||
|
(Benefit) Provision for income taxes |
( |
) | ||||||||||||||
|
Net income (loss) from discontinued operations, net of taxes |
$ | $ | ( |
) | $ | $ | ||||||||||
In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the condensed consolidated statements of cash flows. Results related to the Wound Care Trademarks for the nine months ended September 30, 2025 and 2024 have been reflected as discontinued operations in the condensed consolidated statements of cash flows and consist of the following (in thousands):
|
Nine Months Ended September 30, |
||||||||
|
2025 |
2024 |
|||||||
|
Operating activities: |
||||||||
|
Net income from discontinued operations |
$ | $ | ||||||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
|
Non-cash gain on divestiture |
( |
) | ||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
||||||||
|
Inventory |
||||||||
|
Prepaid expenses and other current assets |
||||||||
|
Accounts payable and accrued liabilities |
( |
) | ( |
) | ||||
|
Net cash provided by operating activities, discontinued operations |
||||||||
|
Investing activities: |
||||||||
|
Proceeds from divestiture |
||||||||
|
Net cash provided by investing activities, discontinued operations |
||||||||
|
Net increase in cash and cash equivalents, discontinued operations |
$ | $ | ||||||
NOTE 16. DERMADOCTOR DIVESTITURE
On March 12, 2024, the Company entered into an agreement to sell
In accordance with the provisions of ASC 205-20, Presentation of Financial Statements: Discontinued Operations (“ASC 205-20”), the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the condensed consolidated statements of operations. The results of DERMAdoctor’s operations for the three and nine months ended September 30, 2025 and 2024 have been reflected as discontinued operations in the condensed consolidated statements of operations and consist of the following (in thousands):
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Net sales |
$ | $ | $ | $ | ||||||||||||
|
Cost of goods sold |
||||||||||||||||
|
Gross profit |
||||||||||||||||
|
Operating expenses: |
||||||||||||||||
|
Research and development |
||||||||||||||||
|
Sales and marketing |
||||||||||||||||
|
General and administrative |
||||||||||||||||
|
Total operating expenses |
||||||||||||||||
|
Operating loss |
( |
) | ||||||||||||||
|
Loss on divestiture |
( |
) | ||||||||||||||
|
Net loss from discontinued operations |
$ | $ | $ | $ | ( |
) | ||||||||||
In accordance with the provisions of ASC 205-20, the Company has not included in the results of continuing operations the results of operations of the discontinued operations in the condensed consolidated statements of cash flows. The results of DERMAdoctor for the nine months ended September 30, 2025 and 2024 have been reflected as discontinued operations in the condensed consolidated statements of cash flows and consist of the following (in thousands):
|
Nine Months Ended September 30, |
||||||||
|
2025 |
2024 |
|||||||
|
Operating activities: |
||||||||
|
Net loss from discontinued operations |
$ | $ | ( |
) | ||||
|
Adjustments to reconcile net loss to net cash used in operating activities: |
||||||||
|
Non-cash loss on divestiture |
||||||||
|
Changes in operating assets and liabilities: |
||||||||
|
Accounts receivable |
( |
) | ||||||
|
Inventory |
||||||||
|
Prepaid expenses and other current assets |
( |
) | ||||||
|
Other assets |
||||||||
|
Accounts payable and accrued liabilities |
||||||||
|
Operating lease liabilities |
( |
) | ||||||
|
Net cash used in operating activities, discontinued operations |
( |
) | ||||||
|
Investing activities: |
||||||||
|
Proceeds from divestiture |
||||||||
|
Cash transferred to New Age Investments, LLC |
( |
) | ||||||
|
Net cash provided by investing activities, discontinued operations |
||||||||
|
Net increase in cash and cash equivalents, discontinued operations |
$ | $ | ||||||
NOTE 17. INCOME TAXES
The provision for income taxes is recorded at the end of each interim period based on the Company’s best estimate of its effective income tax rate expected to be applicable for the full fiscal year, adjusted for any discrete items during the quarter. The Company has recorded an income tax provision of $
NOTE 18. RELATED PARTY TRANSACTIONS
The following table summarizes information about the Company’s related party revenue and cost of goods sold (in thousands):
|
Three Months Ended September 30, |
Nine Months Ended September 30, |
|||||||||||||||
|
2025 |
2024 |
2025 |
2024 |
|||||||||||||
|
Chongqing Pioneer Pharma Holdings Limited: |
||||||||||||||||
|
Net sales |
$ | $ | $ | $ | ||||||||||||
|
Cost of goods sold |
||||||||||||||||
Related party accounts receivable were $
NOTE 19. SUBSEQUENT EVENTS
The Company has evaluated all subsequent events through the filing date of this Form 10-Q with the SEC, to ensure that this filing includes appropriate disclosure of events both recognized in the condensed consolidated financial statements as of September 30, 2025, and events which occurred subsequently but were not recognized in the condensed consolidated financial statements. Except as described below, there were no subsequent events which required recognition, adjustment to, or disclosure in, the unaudited condensed consolidated financial statements.
Submission of Matters to a Vote of Security Holders and Annual Meeting
On October 16, 2025, the Company held its annual meeting of stockholders. Matters considered at that meeting are relevant to certain subsequent events outlined below. Additional details and information about other matters submitted to a vote of security holders and related results of the meeting can be found in the Company’s Current Report on Form 8-K filed on October 20, 2025.
Increase in Shares Authorized Under 2017 Plan
On October 16, 2025, stockholders approved an amendment to increase the shares authorized under the 2017 Plan by
Series E Preferred Stock Closing and Conversion to Common Stock
The 2025 Preferred Stock Purchase Agreement dated as of August 19, 2025 between the Company and Mr. Lazar provided for the ability of Mr. Lazar to assign, transfer and/or sell his shares of Series D Preferred Stock, Series E Preferred Stock, the shares of Common Stock underlying the Transferred Stock (as defined below) and/or his right acquire such securities (see Note 8, “Financing Activities”). On October 9, 2025, Mr. Lazar tendered his resignation as Chief Executive Officer and a director of NovaBay and entered into a securities purchase agreement with R01 Fund LP (“R01”) and Framework Ventures IV L.P. (“Framework” and, together with R01, the “Purchasers”) to effect such transfer. Pursuant to the agreement, Mr. Lazar assigned to the Purchasers all of Mr. Lazar’s right, title and interest in (i)
October 2025 Pre-Funded Warrants
On October 16, 2025, the Company issued and sold pre-funded warrants (the “October 2025 Pre-Funded Warrants”) to purchase
an aggregate of
NYSE Compliance
On October 20, 2025, the Company was notified by NYSE American that the Company had regained compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide.
Series D Preferred Stock Conversion to Common Stock
On October 21, 2025, three business days after the Conversion Approval, the
Redemption of Series F Preferred Stock
Subsequent to September 30, 2025,
|
ITEM 2. |
MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS |
This discussion contains forward-looking statements that involve risks and uncertainties. The following discussion of our financial condition and results of operations should be read together with our unaudited condensed consolidated financial statements and related notes included in Part I, Item 1 of this report, and with our consolidated financial statements and related notes, and Management’s Discussion and Analysis of Financial Condition and Results of Operations, included in our 2024 Annual Report. Words such as “expects,” “anticipated,” “will,” “may,” “goals,” “plans,” “believes,” “estimates,” “concludes,” “determines,” variations of these words, and similar expressions are intended to identify these forward-looking statements. As a result of the significant changes that have occurred to us and our business as a result of completing the Avenova Asset Divestiture and the PhaseOne Divestiture, the 2025 Preferred Stock Issuance and the sale of the October 2025 Pre-Funded Warrants, the expected additional changes that will occur when we determine and proceed with the future strategic direction of our Company, as well as other factors, including those set forth under the section titled “Risk Factors” in Part I, Item 1A. of this Quarterly Report and the section titled “Risk Factors” in Part I, Item 1A. of our 2024 Annual Report, as well as in other sections in our SEC filings, our actual results may differ materially from those anticipated in these forward-looking statements. Readers are cautioned that these forward-looking statements are only predictions based upon assumptions made that we believed to be reasonable at the time and are subject to risks and uncertainties. Therefore, actual results may differ materially and adversely from those expressed in any forward-looking statements. Except as required by law, we undertake no obligation to revise or update publicly any forward-looking statements after the date of this report, even if new information becomes available in the future.
Overview
We were previously focused on the development and sale of eyecare, wound care, and skin care products. The Company may continue to manufacture wound care products domestically in the United States and export finished goods to China.
|
● |
The Avenova Asset Divestiture closed on January 17, 2025 in which we sold our primary eyecare business (see Note 14, “Avenova Asset Divestiture and Bridge Loan” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report); |
|
|
● |
The PhaseOne Divestiture closed on January 8, 2025 in which we sold our PhaseOne trademark (see Note 15, “PhaseOne Divestiture” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report); and |
|
|
● |
The DERMAdoctor Divestiture closed on March 12, 2024 in which we sold our primary skin care business (see Note 16, “DERMAdoctor Divestiture” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report). |
Discontinued Operations
Historical financial results related to each of the businesses that we divested above in the Avenova Asset Divestiture, the PhaseOne Divestiture and the DERMAdoctor Divestiture are presented as discontinued operations in the unaudited condensed consolidated financial statements included in this report. See Notes 14, “Avenova Asset Divestiture and Bridge Loan,” 15 “PhaseOne Divestiture” and 16, “DERMAdoctor Divestiture” to the Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report for additional details.
Previous Plan of Dissolution and Strategic Direction of the Company
The Company’s Board unanimously approved each of the divestitures above and subsequently evaluated additional strategic options available to the Company. During this time, the Board pursued the Dissolution pursuant to Plan of Dissolution which was approved at the 2025 Special Meeting (see Note 1, “Organization” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report). Although stockholder approval of the Dissolution was received, the Board was authorized to subsequently determine, in its discretion, whether or not to proceed with the Dissolution. The Board ultimately determined not to pursue the Dissolution and simultaneously entered into the 2025 Preferred Stock Purchase Agreement (see Note 8, “Financing Activities” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report), Series E Preferred Stock Closing (see Note 19, “Subsequent Events” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report) and October 2025 Pre-Funded Warrants (see Note 19, “Subsequent Events” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report). As part of its broader capital allocation review, the Company has begun evaluating opportunities within emerging financial infrastructure and network-based markets. These opportunities may include select blockchain-based assets that the Company believes could enhance capital efficiency and long-term stockholder value.
NYSE American Notices
On April 18, 2024, the Company received a notification from the NYSE American LLC Exchange (“NYSE American”) stating that the Company is not in compliance with Section 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the NYSE American Company Guide (requiring stockholders’ equity of (i) $2.0 million or more if the Company has reported losses from continuing operations and/or net losses in two of its three most recent fiscal years; (ii) $4.0 million or more if the Company has reported losses from continuing operations and/or net losses in three of the four most recent fiscal years and (iii) $6.0 million or more if the Company has reported losses from continuing operations and/or net losses in its five most recent fiscal years, respectively.
On October 20, 2025, the Company was notified by NYSE American that the Company had regained compliance with the minimum stockholders’ equity requirements of Sections 1003(a)(i), 1003(a)(ii) and 1003(a)(iii) of the Company Guide.
Financial Overview and Outlook
Based on our funds available on September 30, 2025, together with net proceeds from the issuance of the Series E Preferred Stock and October 2025 Pre-Funded Warrants (see Note 19, “Subsequent Events” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report), management believes that the Company’s existing cash and cash equivalents will be sufficient to enable the Company to meet its planned operating expenses at least through November 7, 2026; however, as referenced above, the Company is considering adjustments to its strategic direction. As a result of any changes in the Company’s strategic direction, there may be circumstances that cause the Company to adjust its anticipated spending in the near term.
Critical Accounting Estimates
Our unaudited condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. The preparation of these unaudited condensed consolidated financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the unaudited condensed consolidated financial statements, as well as the reported revenues and expenses during the reporting periods. In preparing these unaudited condensed consolidated financial statements, management has made its best estimates and judgments of certain amounts, giving due consideration to materiality. On an ongoing basis, we evaluate our estimates and judgments. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances. Actual results may differ from these estimates.
While our significant accounting policies are more fully described in Note 2, “Summary of Significant Accounting Policies” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report, we believe that the following accounting estimates are most critical to fully understanding and evaluating our reported financial results as discussed in this Management’s Discussion and Analysis of Financial Condition and Results of Operations, particularly taking into account the significant changes that occurred to our business as a result of the closing of the Avenova Asset Divestiture and the PhaseOne Divestiture in January 2025.
Impairment of Assets
We review long-lived assets for impairment at least annually or whenever events or changes in business circumstances indicate that any such asset may be impaired, that the carrying amount of any such asset may not be fully recoverable or that the useful life of the asset, if applicable, is no longer appropriate. Management uses judgement in making critical assumptions and estimates in determining when an impairment assessment should be recorded, if more frequent than annually, or in the completion of any such assessment. This includes cash flow projections that look several years into the future and assumptions on variables such as economic conditions, probability of success, and discount rates. Changes in judgments with respect to these assumptions and estimates could impact any such impairments recorded such as those recorded in the first and third quarter of 2025 as further described in Notes 2, “Summary of Significant Accounting Policies;” 5, “Property and Equipment;” and 7, “Commitments and Contingencies” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report.
Common Stock Warrant Liabilities
For warrants that are classified as liabilities, the Company records the fair value of the warrants upon issuance and at each balance sheet date with changes in the estimated fair value recorded as a non-cash gain or loss in the unaudited condensed consolidated statements of operations. The fair values of these warrants are determined using the Black Scholes option pricing model. These values are subject to a significant degree of management’s judgment.
Results of Operations
Comparison of the Three Months Ended September 30, 2025 and 2024 (dollars in thousands)
|
Three Months Ended September 30, |
Dollar |
Percent |
||||||||||||||
|
2025 |
2024 |
Change |
Change |
|||||||||||||
|
Statement of Operations |
||||||||||||||||
|
Sales: |
||||||||||||||||
|
Product revenue, net |
$ | 521 | — | $ | 521 | 100 | % | |||||||||
|
Cost of goods sold |
479 | — | 479 | 100 | % | |||||||||||
|
Gross profit |
42 | — | 42 | 100 | % | |||||||||||
|
Operating expenses |
||||||||||||||||
|
General and administrative |
1,211 | 1,703 | (492 | ) | (29 | )% | ||||||||||
|
Impairment of long-lived assets |
87 | — | 87 | 100 | % | |||||||||||
|
Total operating expenses |
1,298 | 1,703 | (405 | ) | (24 | )% | ||||||||||
|
Operating loss |
(1,256 | ) | (1,703 | ) | 447 | (26 | )% | |||||||||
|
Extinguishment of Secured Convertible Note |
— | (13 | ) | 13 | (100 | )% | ||||||||||
|
Accretion of interest and amortization of discounts on convertible notes |
— | (138 | ) | 138 | (100 | )% | ||||||||||
|
Other expense, net |
(77 | ) | — | (77 | ) | 100 | % | |||||||||
|
Net loss from continuing operations |
(1,333 | ) | (1,854 | ) | 521 | (28 | )% | |||||||||
|
Net income from discontinued operations, net of taxes |
40 | 642 | (602 | ) | (94 | )% | ||||||||||
|
Net loss |
$ | (1,293 | ) | $ | (1,212 | ) | $ | (121 | ) | (7 | )% | |||||
Impact of Divestitures
Financial results related to divested assets from the Avenova Asset Divestiture and the PhaseOne Divestiture for the three months ended September 30, 2025 and 2024 have been aggregated and reported for each of these periods in the line item titled “Net income from discontinued operations, net of taxes” in the table above. See additional information in Notes 14, “Avenova Asset Divestiture and Bridge Loan;” and 15, “PhaseOne Divestiture;” in Notes to the Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report for additional details regarding these financial results for the periods presented. The discussions below and throughout this section apply only to results from our continuing operations except as otherwise noted.
Total Net Sales and Cost of Goods Sold
Product revenue, net, increased $0.5 million, or 100%, to $0.5 million for the three months ended September 30, 2025.
Revenue and cost of goods sold recorded during the three months ended September 30, 2025 was from the Company’s wound care business sold to our Chinese distributor with no comparable order in the three months ended September 30, 2024.
General and administrative
General and administrative expenses decreased $0.5 million, or 29%, to $1.2 million for the three months ended September 30, 2025, from $1.7 million for the three months ended September 30, 2024, due primarily to a decrease in outside services costs related to non-recurring strategic initiatives, including the Avenova Asset Divestiture, the PhaseOne Divestiture, and evaluating and pursuing various strategic options for our Company.
Impairment of Long-Lived Assets
During the three months ended September 30, 2025, the Company recorded an impairment for right-of-use assets associated with leases of $84 thousand and $3 thousand for fixed assets including leasehold improvements.
Extinguishment of Secured Convertible Notes
Extinguishment of Secured Convertible Notes was $13 thousand for the three months ended September 30, 2024, with no comparable activity for the three months ended September 30, 2025.
Accretion of interest and amortization of discounts on convertible notes
Accretion of interest and amortization of discounts on convertible notes was $0.1 million for the three months ended September 30,
2024, with no comparable activity for the three months ended September 20, 2025.
Other expense, net
Other expense, net was $77 thousand for the three months ended September 30, 2025, with no comparable activity for the three months ended September 30, 2024.
Comparison of the Nine Months Ended September 30, 2025 and 2024 (dollars in thousands)
|
Nine Months Ended September 30, |
Dollar |
Percent |
||||||||||||||
|
2025 |
2024 |
Change |
Change |
|||||||||||||
|
Statement of Operations |
||||||||||||||||
|
Sales: |
||||||||||||||||
|
Product revenue, net |
$ | 521 | — | $ | 521 | 100 | % | |||||||||
|
Cost of goods sold |
479 | — | 479 | 100 | % | |||||||||||
|
Gross profit |
42 | — | 42 | 100 | % | |||||||||||
|
Operating expenses |
||||||||||||||||
|
General and administrative |
5,803 | 5,611 | 192 | 3 | % | |||||||||||
|
Impairment of long-lived assets |
676 | — | 676 | 100 | % | |||||||||||
|
Total operating expenses |
6,479 | 5,611 | 868 | 15 | % | |||||||||||
|
Operating loss |
(6,437 | ) | (5,611 | ) | (826 | ) | 15 | % | ||||||||
|
Non-cash gain on changes in fair value of warrant liabilities |
— | 114 | (114 | ) | (100 | )% | ||||||||||
|
Non-cash (loss) gain on change in fair value of embedded derivative liability |
— | (18 | ) | 18 | (100 | )% | ||||||||||
|
Extinguishment of Secured Convertible Note |
— | (13 | ) | 13 | (100 | )% | ||||||||||
|
Accretion of interest and amortization of discounts on convertible notes |
— | (871 | ) | 871 | (100 | )% | ||||||||||
|
Other expense, net |
(190 | ) | (453 | ) | 263 | (58 | )% | |||||||||
|
Net loss from continuing operations |
(6,627 | ) | (6,852 | ) | 225 | (3 | )% | |||||||||
|
Net income from discontinued operations, net of taxes |
11,082 | 841 | 10,201 | 1,213 | % | |||||||||||
|
Net income (loss) |
$ | 4,455 | $ | (6,011 | ) | $ | 10,466 | (174 | )% | |||||||
Impact of Divestitures
Financial results related to divested assets from the Avenova Asset Divestiture and the PhaseOne Divestiture for the nine months ended September 30, 2025 and from the DERMAdoctor Divestiture for the nine months ended September 30, 2024 have been aggregated and reported for each of these periods in the line item titled “Net income from discontinued operations, net of taxes” in the table above. See additional information in Notes 14, “Avenova Asset Divestiture and Bridge Loan;” 15, “PhaseOne Divestiture;” and 16, “DERMAdoctor Divestiture” in Notes to the Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report for additional details regarding these financial results for the periods presented. The discussions below and throughout this section apply only to results from our continuing operations except as otherwise noted.
Total Net Sales and Cost of Goods Sold
Product revenue, net, increased $0.5 million, or 100%, to $0.5 million for the nine months ended September 30, 2025.
Revenue and cost of goods sold recorded during the nine months ended September 30, 2025 was from the Company’s wound care business sold to our Chinese distributor with no comparable order in the nine months ended September 30, 2024.
General and administrative
General and administrative expenses increased $0.2 million, or 3%, to $5.8 million for the nine months ended September 30, 2025, from $5.6 million for the nine months ended September 30, 2024, due primarily to an increase in outside services costs related to non-recurring strategic initiatives, including evaluating and pursuing various strategic options for our Company.
Impairment of Long-Lived Assets
During the nine months ended September 30, 2025, the Company recorded an impairment for right-of-use assets associated with leases of $643 thousand and $33 thousand for fixed assets including leasehold improvements.
Non-cash gain on changes in fair value of warrant liability
Adjustments to the fair value of warrant liabilities resulted in a gain of $0.1 million for the nine months ended September 30, 2024 with no comparable adjustment for the nine months ended September 30, 2025. For additional information regarding warrant liabilities and their valuation, please see Note 3, “Fair Value Measurements” and Note 10, “Common Stock Warrants” in the Notes to Unaudited Condensed Consolidated Financial Statements, (unaudited) in Part I, Item 1 of this report.
Non-cash loss on changes in fair value of embedded derivative liability
Adjustments to the fair value of embedded derivative liability resulted in a loss of $18 thousand for the nine months ended September 30, 2024 with no comparable adjustment for the nine months ended September 30, 2025. For additional information regarding the embedded derivative liability and its valuation, please see Note 3, “Fair Value Measurements” and Note 9, “Convertible Notes” in the Notes to the Condensed Consolidated Financial Statements (unaudited), in Part I, Item 1 of this report.
Accretion of interest and amortization of discounts on convertible notes
Accretion of interest and amortization of discounts on convertible notes was $0.9 million for the nine months ended September 30, 2024 with no comparable result for the nine months ended September 30, 2025. The 2024 result was primarily from the amortization of discount and issuance cost related to the Secured Convertible Notes issued in May 2023 which were fully repaid in the third quarter of 2024. See Note 3, “Fair Value Measurements” and Note 9, “Convertible Notes” in the Notes to the Condensed Consolidated Financial Statements (unaudited), in Part I, Item 1 of this report.
Other expense, net
Other expense, net was $190 thousand for the nine months ended September 30, 2025 and $0.5 million for the nine months ended September 30, 2024. The higher result in the 2024 period was due to issuance costs incurred for the March 2024 Warrant and the Unsecured Convertible Notes issued in March 2024. See Note 9, “Convertible Notes” and Note 10, “Common Stock Warrants” in the Notes to the Condensed Consolidated Financial Statements (unaudited), in Part I, Item 1 of this report.
Financial Condition, Liquidity and Capital Resources
We have largely incurred net losses and generated negative cash flows from operations since inception and may incur losses as we pursue our new strategic direction. As of September 30, 2025, our cash and cash equivalents were $2.3 million, compared to $430 thousand as of December 31, 2024. Based on our funds available on September 30, 2025, together with net proceeds from the issuance of the Series E Preferred Stock and October 2025 Pre-Funded Warrants (see Note 19, “Subsequent Events” in the Notes to Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report), management believes that the Company’s existing cash and cash equivalents will be sufficient to enable the Company to meet its planned operating expenses at least through November 7, 2026; however, as referenced above, the Company is considering adjustments to its strategic direction. As a result of any changes in the Company’s strategic direction, there may be circumstances that cause the Company to adjust its anticipated spending in the near term.
Net Cash Used in Operating Activities, Continuing Operations
Net cash used in operating activities from continuing operations was $6.2 million for the nine months ended September 30, 2025, which consisted primarily of a net loss from continuing operations of $6.6 million, adjusted by depreciation and amortization expenses of $5 thousand, stock-based compensation expenses related to employee and director stock awards of $6 thousand, non-cash right-of-use asset amortization of $0.1 million, non-cash impairment of long-lived assets of $0.7 million, accretion of interest and amortization of debt discounts on convertibles notes of $84 thousand, and a net increase of $0.4 million in our net operating assets and liabilities of continuing operations.
Net cash used in operating activities from continuing operations was $5.8 million for the nine months ended September 30, 2024, which consisted primarily of a net loss from continuing operations of $6.0 million, adjusted by depreciation and amortization expenses of $24 thousand, stock-based compensation expenses related to employee and director stock awards of $0.1 million, non-cash expense incurred to obtain consent of Secured Convertible Note holders in connection with the DERMAdoctor Divestiture of $0.4 million, non-cash gain on changes in fair value of warrant liability of $0.1 million, non-cash loss on changes in fair value of embedded derivative liability of $18 thousand, non-cash loss on modification of warrants of $69 thousand, non-cash right-of-use asset amortization of $254 thousand, accretion of interest and amortization of debt discounts on convertibles notes of $0.9 million, and a net increase of $0.6 million in our net operating assets and liabilities of continuing operations.
Cash Used in Investing Activities, Continuing Operations
Net cash used in investing activities from continuing operations was $2 thousand for the nine months ended September 30, 2024, which consisted of purchases of property and equipment. There was no cash used in, or provided by, investing activities from continuing operations during the nine months ended September 30, 2025.
Cash Used in Financing Activities, Continuing Operations
Net cash used in financing activities from continuing operations was $3.2 million for the nine months ended September 30, 2025, which consisted primarily of $2.0 million in cash payments to repurchase outstanding warrants, a $0.5 million repayment of the Bridge Note, and dividend paid of $4.8 million. Offsetting these payments were $0.9 million in proceeds from warrant exercises and $3.8 million in proceeds from the Lazar Purchase Agreement.
Net cash provided by financing activities from continuing operations was $1.0 million for the nine months ended September 30, 2024,
which included repayment of $2.0 million for the Secured Convertible Notes through September 30, 2024, net proceeds of $2.9 million from the 2024 Public Offering transaction, and the net proceeds of $0.2 million from the 2024 Warrant Repice transaction.
Net Operating Losses and Tax Credit Carryforwards
As of December 31, 2024, we had net operating loss carryforwards for federal and state income tax purposes of $153.7 million and $128.6 million, respectively. The federal net operating loss carryforwards consist of $94.9 million generated before January 1, 2018, which will begin to expire in 2025 and $59.6 million generated after December 31, 2017, that will carry forward indefinitely but are subject to an 80% limitation for years following December 31, 2021. The state net operating loss carryforwards will begin to expire in 2028. As of December 31, 2024, we also had tax credit carryforwards of $0.5 million for federal income tax purposes and $0.1 million for state tax purposes. If not utilized, the federal tax credits will begin expiring in 2031. The state tax credits have an indefinite carryover period.
Current federal and California tax laws include substantial restrictions on the utilization of net operating loss carryforwards in the event of an ownership change of a corporation. Accordingly, our ability to utilize net operating loss carryforwards may be limited as a result of such ownership changes. Such a limitation could result in the expiration of carryforwards before they are utilized.
Inflation
Our costs and operating expenses are subject to fluctuations, particularly historically due to changes in the cost of labor and service providers. As a result of our recent changes to our business and reduced operations, our future business results will depend, in part, on our continued ability to manage these fluctuations through cost savings projects and sourcing decisions. Failure to manage these fluctuations could adversely impact our results of operations or cash flows.
Off-Balance Sheet Arrangements
We did not have any “off-balance sheet arrangements” as defined in Item 303(b)(1)(ii)(B) of Regulation S-K at September 30, 2025 or December 31, 2024.
Seasonality
Our NeutroPhase branded product is sold through our distribution partner in China; therefore, we receive periodic large orders that result in large chunks of revenue that are received in irregular intervals.
Contractual Obligations
In the normal course of business, we have historically entered into contracts and commitments that obligate us to make payments in the future and we expect to enter into contracts and commitments on behalf of the Company in connection with our evolving strategic direction. Information regarding our obligations under lease and convertible note arrangements are provided in Notes 7 and 9, respectively, in the Notes to the Condensed Consolidated Financial Statements (unaudited) in Part I, Item 1 of this report.
|
ITEM 3. |
QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK |
Our market risk consists principally of interest rate risk on our cash and cash equivalents. Our exposure to market risk is limited primarily to interest income sensitivity, which is affected by changes in interest rates, particularly because our current liquid assets at September 30, 2025 were held in cash and cash equivalents.
Our investment policy restricts our investments to high-quality investments and limits the amounts invested with any one issuer, industry, or geographic area. The goals of our investment policy are as follows: preservation of capital, assurance of liquidity needs, best available return on invested capital, and minimization of capital taxation. Some of the securities in which we invest may be subject to market risk. This means that a change in prevailing interest rates may cause the principal amount of the investment to fluctuate. For example, if we hold a security that was issued with an interest rate fixed at the then-prevailing rate and the prevailing interest rate later rises, the principal amount of our investment will probably decline. To minimize this risk, in accordance with our investment policy, we maintain our cash and cash equivalents in short-term marketable securities, including money market mutual funds, Treasury bills, Treasury notes, certificates of deposit, commercial paper, and corporate and municipal bonds. The risk associated with fluctuating interest rates is limited to our investment portfolio. Due to the short-term nature of our investment portfolio, we believe we have minimal interest rate risk arising from our investments. As of September 30, 2025 and December 31, 2024, a 10% change in interest rates would have had an immaterial effect on the value of our investment portfolio. We do not use derivative financial instruments in our investment portfolio. We do not hold any instruments for trading purposes.
With most of our focus on the domestic U.S. market, we have not had any material exposure to foreign currency rate fluctuations.
|
ITEM 4. |
CONTROLS AND PROCEDURES |
Evaluation of Disclosure Controls and Procedures
As of the end of the period covered by this report, we carried out an evaluation, under the supervision and with the participation of our management, including our Chief Executive Officer and Chief Financial Officer, of the effectiveness of our disclosure controls and procedures pursuant to Rule 13a-15 and 15d-15 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).
A control system, no matter how well conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Assessing the costs and benefits of such controls and procedures necessarily involves the exercise of judgment by management. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
Based upon that evaluation at September 30, 2025, our Chief Executive Officer and our Chief Financial Officer concluded that our disclosure controls and procedures were effective to ensure, at the reasonable assurance level, that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in the SEC's rules and forms and were effective in ensuring that information required to be disclosed by us in the reports that we file or submit under the Exchange Act was accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.
Changes in Internal Control Over Financial Reporting
There were no changes in our internal control over financial reporting during the current quarter which has materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
PART II. OTHER INFORMATION
|
ITEM 1. |
LEGAL PROCEEDINGS |
From time to time, the Company may be involved in various legal proceedings arising in the ordinary course of business. As of September 30, 2025, there were no matters that, in the opinion of management, would ultimately result in liability that would have a material adverse effect on the Company’s financial position, results of operations or cash flows.
|
ITEM 1A. |
RISK FACTORS |
For information regarding factors that could affect our business, results of operations, financial condition and liquidity, see the risk factors discussed under Part I, Item 1A included in our 2024 Annual Report.
The Company is supplementing the risk factors previously disclosed in our 2024 Annual Report with the following risk factors.
Risks Related to Our Proposed Strategy Focusing on Assets Within Emerging Decentralized Financial Infrastructure and Network-Based Markets
We are considering shifting a portion of our business strategy by evaluating opportunities within emerging decentralized financial infrastructure and network-based markets, which may include select blockchain based assets and we may be unable to successfully implement this new strategy.
We are considering shifting a portion of our business strategy by evaluating opportunities within emerging decentralized financial infrastructure and network-based markets, which may include select blockchain-based assets, including through staking, restaking, liquid staking and other decentralized finance activities. The Company’s review of such opportunities is preliminary in nature, and there can be no assurance that any particular transaction, investment, or strategic initiative will be pursued or consummated. These evaluations remain subject to ongoing diligence, market conditions, regulatory considerations, and approval by the Board, as appropriate. Any potential activity in this area would be conducted in a manner consistent with the Company’s existing compliance framework and applicable laws and regulations. This strategic shift would require specialized employee skillsets and operational, technical and compliance infrastructure to support stablecoin and related staking activities. This would also require that we implement different security protocols and treasury management practices. Further, there is ongoing scrutiny and limited formal guidance from regulatory agencies, including NYSE and the SEC, with respect to the treatment of similar strategies from other public companies. There is no assurance that we will be able to execute this strategy by building out the needed infrastructure within the timeframe that we currently anticipate. Errors by key management could result in significant loss of funds and reduced rewards. As a result, our shift towards blockchain-based assets could have a material adverse effect on our business and financial condition.
Our potential shift towards a business strategy focused on emerging decentralized financial infrastructure and blockchain-based assets would require substantial changes in our day-to-day operations and exposes us to significant operational risks.
Our potential shift towards a strategy focused on emerging decentralized financial infrastructure and blockchain-based assets, including staking, restaking, liquid staking, and other decentralized finance activities, exposes us to significant operational risks. They may also require that we maintain constant up time to ensure that we are eligible for staking rewards and to avoid penalties. In addition, the decentralized financial infrastructure and network-based markets ecosystem rapidly evolves, with frequent upgrades and protocol changes that may require significant adjustments to our operational setup. The upgrades and protocol changes may require that we incur unanticipated costs. We may also need to employ third-party service providers in our operations, which may introduce risks outside of our control, including significant cybersecurity risks. Any of these operational risks could materially and adversely affect our ability to execute our strategy, prevent us from realizing positive returns and severely hurt our financial condition.
Adverse changes in the regulatory treatment of blockchain-based assets could materially impair the value and liquidity of our future holdings and negatively impact our business, financial condition, and results of operations going forward.
The legal and regulatory framework governing blockchain-based assets in the United States and in foreign jurisdictions is rapidly evolving and remains highly uncertain. Federal, state, and foreign regulators continue to issue new rules and take enforcement actions that directly or indirectly affect the classification, transferability, custody, and tax treatment of blockchain-based assets. Should any such asset we purchase, or the activities of any party critical to the blockchain ecosystem (including exchanges, validators, or custodians), be deemed to violate securities, commodities, anti-money-laundering, sanctions, consumer-protection, or other applicable laws, we could become subject to significant fines, penalties, registration requirements, trading restrictions, or forced divestiture of such blockchain-based assets. Any such development could cause a precipitous decline in the market price of such assets, impair our ability to monetize or otherwise use our blockchain-based asset treasury, and adversely impact the market price of our securities.
Risks Related to Blockchain-Based Assets
The blockchain-based asset trading platforms on which assets within emerging financial infrastructure and network-based markets trade are relatively new and largely unregulated or may not be complying with existing regulations.
The blockchain-based assets that we are evaluating primarily trade on blockchain-based asset trading platforms and decentralized finance protocols which are relatively new and, in many ways, are not subject to, or may not comply with, regulation in relevant jurisdictions in a manner similar to other regulated trading platforms, such as national securities exchanges or designated contract markets. While many of these relatively new trading platforms provide the public with information regarding their ownership structure, management teams, private key management, hot/cold storage policies, on-chain activities, capitalization, corporate practices and regulatory compliance, many other relatively new trading platforms do not. In particular, those located outside the United States may be subject to significantly less stringent regulatory and compliance requirements in their local jurisdictions.
The trading platforms on which the blockchain-based assets that we are evaluating trade may be unpredictable and susceptible to attacks.
Significant trading may occur on systems and platforms with minimum predictability. Spot markets may impose daily, weekly, monthly or customer-specific transaction or withdrawal limits or suspend withdrawals entirely, rendering the exchange of blockchain-based assets for fiat currency difficult or impossible. Further, participation in spot markets requires users to take on credit risk by transferring blockchain-based assets from a personal account to a third-party’s account.
Additionally, tools to detect and deter fraudulent or manipulative trading activities (such as market manipulation, front-running of trades, and wash-trading) may not be available to or employed by such trading platforms or may not exist at all. As a result, the marketplace may lose confidence in, or may experience problems relating to, these venues and the blockchain-based assets that trade on these venues. No trading platform on which blockchain-based assets trade is immune from these risks. The closure or temporary shutdown of such trading platforms due to fraud, business failure, hackers or malware, or government-mandated regulation may reduce confidence in blockchain-based assets and other assets within emerging financial infrastructure and network-based markets and can slow down the mass adoption of it. Further, trading platform failures can have an adverse effect on blockchain-based markets and the price of blockchain-based assets and could therefore have a negative impact on the performance of our Common Stock.
The trading prices of many blockchain-based assets have experienced extreme volatility in recent periods and may continue to do so. Extreme volatility in the future, including further declines in trading prices, could have a material adverse effect on the value of our common stock and the common stock could lose all or substantially all of its value.
The trading prices of many blockchain-based assets have experienced extreme volatility in recent periods and may continue to do so. For instance, there were steep increases in the value of certain blockchain-based assets over the course of 2021, and multiple market observers asserted that blockchain-based assets were experiencing a “bubble.” These increases were followed by steep drawdowns throughout 2022. Prices of such blockchain-based assets continued to fluctuate widely throughout 2023 and through this date.
Extreme volatility in the future could have a material adverse effect on the value of our common stock and our common stock could lose all or substantially all of its value. Furthermore, negative perception and a lack of stability and standardized regulation in the blockchain-based economy may reduce confidence in the blockchain-based economy and may result in greater volatility in the price of blockchain-based assets, including a depreciation in value.
|
ITEM 2. |
UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS |
2025 Preferred Stock Purchase Agreement
On August 19, 2025, the Company entered into 2025 Preferred Stock Purchase Agreement with David E. Lazar, that provides for the Company to sell in a private placement (i) an aggregate of 481,250 shares of Series D Preferred Stock convertible into an aggregate of 77.0 million shares of Common Stock for $3.85 million and (ii) an aggregate of 268,750 shares of Series E Preferred Stock convertible into an aggregate of 43.0 million shares of Common Stock for an additional $2.15 million.
Simultaneous to entering into the 2025 Preferred Stock Purchase Agreement on August 19, 2025, Mr. Lazar completed the Initial Series D Preferred Purchase. The 2025 Preferred Stock Purchase Agreement provided for the ability of Mr. Lazar to assign, transfer and/or sell his shares of Series D Preferred Stock, Series E Preferred Stock, and/or his right acquire such securities. As further described in Note 19, “Subsequent Events”, on October 9, 2025, Mr. Lazar entered into an agreement to effect such transfer.
Since the Common Stock is currently listed on the NYSE American, and among these requirements are Section 713(a) and (b) of the Company Guide. Section 713(a) of the Company Guide requires stockholder approval in connection with any transaction, other than a public offering, involving the sale, issuance, or potential issuance, of common stock or securities convertible into common stock, equal to 20.0% or more of presently outstanding stock for less than the greater of book or market value. Section 713(b) of the Company Guide requires stockholder approval of a transaction, other than a public offering, involving the sale, issuance or potential issuance by an issuer of common stock (or securities convertible into, or exercisable for, common stock) when the issuance or potential issuance of additional shares may result in a change of control of the issuer. As a result of the significant number of shares of Common Stock that may be issued upon the future conversion of the Series D Preferred Stock and Series E Preferred Stock compared to the currently issued and outstanding shares of Common Stock as provided above, the Company was required to obtain stockholder approval in accordance with the Company Guide Rule 713(a) and Rule 713(b) for Conversion Approval.
Conversion Approval was obtained subsequent to September 30, 2025, on October 16, 2025.
On October 16, 2025, subsequent to September 30, 2025 and the Conversion Approval, the Company completed the sale of 268,750 shares of Series E Preferred Stock at a price of $8.00 per share for aggregate gross proceeds of $2.15 million.
Series E Preferred Stock Closing
The 2025 Preferred Stock Purchase Agreement dated as of August 19, 2025 between the Company and Mr. Lazar provided for the ability of Mr. Lazar to assign, transfer and/or sell his shares of Series D Preferred Stock, Series E Preferred Stock, the shares of Common Stock underlying the Transferred Stock and/or his right acquire such securities (see Note 8, “Financing Activities”). On October 9, 2025, Mr. Lazar tendered his resignation as Chief Executive Officer and a director of NovaBay and entered into a securities purchase agreement with the Purchasers to effect such transfer. Pursuant to the agreement, Mr. Lazar agreed to assign to the Purchasers all of the Seller’s right, title and interest in (i) 441,326 outstanding shares of Series D Preferred Stock and (ii) the rights and obligations to purchase the Transferred Stock and the transactions contemplated by the Lazar Sale, each of which were purchased from the Company by Mr. Lazar pursuant to the 2025 Preferred Stock Purchase Agreement. On October 16, 2025, pursuant to the 2025 Preferred Stock Purchase Agreement, the Company filed the certificate of designations relating to the 2025 Preferred Stock Issuance. Each share of Series E Preferred Stock shall convert at the option of the holder or, otherwise, shall automatically convert 30 business days after the Stockholder Approval, into 160 shares of Common Stock, for an aggregate of 43,000,000 shares of Common Stock.
October 2025 Pre-Funded Warrants
On October 16, 2025, the Company issued and sold the October 2025 Pre-Funded Warrants to purchase an aggregate of 5,405,406 shares of Common Stock, to the Purchasers in two transactions for aggregate gross proceeds of approximately $6.0 million The purchase price was $1.10 per October 2025 Pre-Funded Warrant, representing 110% of the closing price of the Common Stock on the day before the issuance, less the $0.01 exercise price for each such October 2025 Pre-Funded Warrant. The October 2025 Pre-Funded Warrants are exercisable for shares of Common Stock at any time after January 1, 2026, subject to receipt of stockholder approval.
|
ITEM 3. |
DEFAULTS UPON SENIOR SECURITIES |
None.
|
ITEM 4. |
MINE SAFETY DISCLOSURES |
Not Applicable.
|
ITEM 5. |
OTHER INFORMATION |
Rule 10b5-1 Trading Arrangements
During the three months ended September 30, 2025, none of our directors or Section 16 officers adopted, modified or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each such term is defined in Item 408 of Regulation S-K.
|
ITEM 6. |
EXHIBITS |
The following exhibits are filed with or incorporated by reference into this report.
EXHIBIT INDEX
|
Incorporation by Reference |
Filed Herewith |
|||||
|
Exhibit Number |
Exhibit Description |
Form |
File Number |
Exhibit/ Form 8-K Item Reference |
Filing Date |
|
|
3.1 |
Amended and Restated Certificate of Incorporation of NovaBay Pharmaceuticals, Inc. |
10-K |
001-33678 |
3.1 |
3/21/2018 |
|
|
3.2 |
Amendment to the Amended and Restated Certificate of Incorporation, dated June 4, 2018 |
8-K |
001-33678 |
3.1 |
6/04/2018 |
|
|
3.3 |
Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 27, 2020 |
8-K |
001-33678 |
3.1 |
5/28/2020 |
|
|
3.4 |
Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 24, 2021 |
8-K |
001-33678 |
3.1 |
5/24/2021 |
|
|
3.5 |
Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated January 31, 2022 |
8-K |
001-33678 |
3.1 |
2/1/2022 |
|
|
3.6 |
Amendment to Amended and Restated Certificate of Incorporation, as amended, dated November 14, 2022 |
8-K |
001-33678 |
3.1 |
11/18/2022 |
|
|
3.7 |
Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated May 30, 2024 |
8-K |
001-33678 |
3.1 |
5/31/2024 |
|
|
3.8 |
Certificate of Designation for the Series B Preferred Stock |
8-K |
001-33678 |
3.1 |
11/1/2021 |
|
|
3.9 |
Certificate of Designation for the Series C Preferred Stock |
8-K |
001-33678 |
3.2 |
11/18/2022 |
|
|
3.10 |
Bylaws, as amended and restated effective June 13, 2023 |
8-K |
001-33678 |
3.1 |
6/14/2023 |
|
|
3.11 |
Certificate of Designation for the Series D Preferred Stock |
8-K |
001-33678 |
3.1 |
8/19/2025 |
|
|
3.12 |
Certificate of Designation for the Series E Preferred Stock |
8-K |
001-33678 |
3.1 |
10/22/2025 |
|
|
3.13 |
Certificate of Designation for the Series F Preferred Stock |
8-K |
001-33678 |
3.3 |
8/19/2025 |
|
|
3.14 |
Amendment to the Amended and Restated Certificate of Incorporation, as amended, dated October 16, 2025 |
8-K |
001-33678 |
3.1 |
10/20/2025 |
|
|
4.1 |
Form of Warrant pursuant to the Services Agreement with TLF Bio Innovation Lab, LLC, dated May 13, 2020 |
8-K |
001-33678 |
4.1 |
5/18/2020 |
|
|
4.2 |
Form of July 2020 Warrant |
8-K |
001-33678 |
4.1 |
7/21/2020 |
|
|
4.3 |
Form of Amended July 2020 Warrant |
8-K |
001-33678 |
4.1 |
9/13/2022 |
|
|
4.4 |
Form of Amended November 2021 Warrant |
8-K |
001-33678 |
4.2 |
9/13/2022 |
|
|
4.5 |
Form of September 2022 Warrant (2020 participants) |
8-K |
001-33678 |
4.3 |
9/13/2022 |
|
|
4.6 |
Form of September 2022 Warrant (2021 participants) |
8-K |
001-33678 |
4.4 |
9/13/2022 |
|
|
4.7 |
Form of Series A-1 Long-Term Warrant |
8-K |
001-33678 |
4.5 |
9/13/2022 |
|
|
4.8 |
Form of Original Issue Discount Secured Senior Convertible Debentures |
8-K |
001-33678 |
4.1 |
4/27/2023 |
|
|
4.9 |
Form of Series B-1 Long-Term Warrant |
8-K |
001-33678 |
4.2 |
4/27/2023 |
|
|
4.10 |
Form of Series B-2 Short-Term Warrant |
8-K |
001-33678 |
4.3 |
4/27/2023 |
|
|
4.11 |
Form of Warrant Amendment Agreement |
8-K |
001-33678 |
4.4 |
4/27/2023 |
|
|
4.12 |
Form of Series C Common Stock Warrant |
8-K |
001-33678 |
4.1 |
12/21/2023 |
|
|
4.13 |
Form of Series D Common Stock Warrant |
8-K |
001-33678 |
4.2 |
3/25/2024 |
|
|
4.14 |
Form of Series E Common Stock Warrant |
8-K |
001-33678 |
4.1 |
6/14/2024 |
|
|
4.15 |
Form of Unsecured Convertible Notes |
8-K |
001-33678 |
4.3 |
3/25/2024 |
|
|
4.16 |
Form of Series F-1 Common Stock Warrant |
8-K |
001-33678 |
4.1 |
7/29/2024 |
|
|
4.17 |
Form of October 2025 Pre-Funded Warrant |
8-K |
001-33678 |
4.1 |
10/20/2025 |
|
|
4.18 |
Amended and Restated Employment Agreement, dated August 19, 2025, by and between the Company and Justin Hall |
8-K |
001-33678 |
10.6 |
8/19/2025 |
|
|
4.19 |
Employment Agreement, dated August 19, 2025, by and between the Company and Tommy Law |
8-K |
000-33678 |
10.7 |
8/19/2025 |
|
|
4.20 |
Settlement Agreement and General and Mutual Release, dated August 19, 2025, by and between the Company and Justin Hall |
8-K |
000-33678 |
10.8 |
8/19/2025 |
|
|
4.21 |
Form of Settlement Agreement and General and Mutual Release with Resigning Non-Employee Directors |
8-K |
000-33678 |
10.9 |
8/19/2025 |
|
|
31.1 |
Certification of the Principal Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) |
X |
||||
|
31.2 |
Certification of the Principal Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(a) or Rule 15d-14(a) |
X |
||||
|
32.1 |
Certification by the Chief Executive Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) |
X |
||||
|
32.2 |
Certification by the Chief Financial Officer of NovaBay Pharmaceuticals, Inc., as required by Rule 13a-14(b) or 15d-14(b) and Section 1350 of Chapter 63 of Title 18 of the United States Code (18 U.S.C. 1350) |
X |
||||
|
101.INS |
Inline XBRL Instance Document |
X |
||||
|
101.SCH |
Inline XBRL Taxonomy Extension Schema Document |
X |
||||
|
101.CAL |
Inline XBRL Taxonomy Extension Calculation Linkbase Document |
X |
||||
|
101.DEF |
Inline XBRL Taxonomy Extension Definition Linkbase |
X |
||||
|
101.LAB |
Inline XBRL Taxonomy Extension Labels Linkbase Document |
X |
||||
|
101.PRE |
Inline XBRL Taxonomy Extension Presentation Linkbase Document |
X |
||||
|
104 |
The Cover Page Interactive Data File, formatted in Inline XBRL (included within the Exhibit 101 attachments) |
X |
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report on Form 10-Q to be signed on its behalf by the undersigned, thereunto duly authorized.
|
Date: November 7, 2025 |
||
|
By: |
/s/ Michael Kazley |
|
|
Michael Kazley Chief Executive Officer (principal executive officer) |
||
|
Date: November 7, 2025 |
||
|
By: |
/s/ Tommy Law |
|
|
Tommy Law Chief Financial Officer (principal financial officer) |
||
FAQ
What were NovaBay (NBY) Q3 2025 results from continuing operations?
How did discontinued operations affect NovaBay’s year-to-date 2025 results?
What is NovaBay’s cash position and equity as of September 30, 2025?
What does management say about NovaBay’s liquidity runway?
How many NovaBay shares were outstanding most recently?
What strategic actions did NovaBay take regarding its brands?
What strategic direction is NovaBay evaluating now?
